ООО "МиниМед", 241520, Российская Федерация, Брянская область, Брянский район, с. Супонево, ул. Шоссейная, 17 А

Тел. (4832) 92-97-97, 92-24-52, -53, -55, -56, -57, -58, -60, -61, -62
Многоканальный номер - 8-800-100-49-32
Факс (4832) 92-24-54, 92-24-59, 92-24-61

ИНН 3234007127 www.minimed.ru e-mail: info@minimed.ru

Регистрационное удостоверение № ФСР 2011/11306 от 07.12.2015 г.

Паспорт

Краситель Азур-эозин по Романовскому (МиниМед-Р)
ТУ 9398-003-29508133-2011

Серия	8-18	Дата изготовления	05.2018 г.	Использовать до	05.2019 г.

1. Назначение

Предназначен для окрашивания форменных элементов крови.

2. Технические требования

Наименование показателя	Норма по ТУ	Результаты испытаний
1 Внешний вид		
1.1 Краситель	Темно-синяя сиропообразная жидкость без нерастворимых примесей	соответствует
1.2 Буфер фосфатный	Прозрачная бесцветная жидкость	соответствует
2. Плотность раствора красителя при комнатной температуре 20±2°С, г/см³	1,000 - 1,100	1,012
3. Время наступления окраски мазка (при разведении красителя 1:19), мин. не более	50	30
4 Окраска форменных элементов крови	эритроциты – розовые с серым оттенком, бежево-коричневые	розовые с серым оттенком
	ядра лейкоцитов – фиолетовые	фиолетовые
	цитоплазма лимфоцитов – голубая, серо-голубая;	голубая
	цитоплазма нейтрофилов – бледно-розовая, серо-розовая;	бледно-розовая
	зернистость нейтрофилов – фиолетовая, красно-фиолетовая,	красно-фиолетовая
	зернистость эозинофилов – желто-оранжевая, розово-фиолетовая;	желто-оранжевая
	зернистость базофилов – фиолетовая	фиолетовая
	тромбоциты – розово-фиолетовые, розово-сине-фиолетовые	розово-фиолетовые

3. Транспортирование и хранение

Транспортирование красителя-фиксатора должно проводиться всеми видами крытого транспорта при температуре от 0 до 25°С в соответствии с правилами перевозки грузов, действующими на данном виде транспорта. Краситель следует хранить при температуре от +5° до +25°С в темном месте, вдали от кислот и щелочей в течение всего срока годности.

4. Гарантии изготовителя

Изготовитель гарантирует соответствие красителя Азур-эозина по Романовскому (МиниМед-Р) требованиям ТУ 9398-003-29508133-2011 при соблюдении потребителем условий транспортирования, применения и течение всего срока годности.

Начальник ПТО **Бабич В.А.**

Declaration of Conformity

HL-7-0664DC DOI 2015/08 (1)

In Application of the Council Directive 98/79/EC on the approximation of the laws of the Member States relating to *In Vitro* Diagnostic Medical Devices & CE marking.

Declaration of conformance to applicable sections of Annex I - Essential Requirements and Annex III (EC Declaration of Conformity) imposed by sections 2 to 5. The below listed products are not classified under Annex II Lists A or B. Access to the appropriate technical files will be made available to the appropriate body in the event this is required.

Product Code	Description	GMDN Classification Code
5267L	Thromboplastin L	55983

I, the undersigned declare that the devices registered against the above GMDN Classification Code conforms to the said Directives.

Full Name: M.J. Stephenson

Title: Managing Director

Signed:

Date: 06 Aug 2015

Tel +44 (0)191 482 8440
Fax +44 (0)191 482 8442
info@helena-biosciences.com
www.helena-biosciences.com

Helena Biosciences Europe
Queensway South, Team Valley Trading Estate,
Gateshead, Tyne and Wear, NE11 0SD,
United Kingdom

Thromboplastin L

REF 5265HL
REF 5265L
REF 5267L

CE IVD

Helena Biosciences Europe, Queensway South, Team Valley Trading Estate, Gateshead, Tyne and Wear, NE11 0SD, United Kingdom
Tel: +44 (0)191 482 8440
Fax: +44 (0)191 482 8442
Email: info@helena-biosciences.com
Web: www.helena-biosciences.com

HL-2-3035P 2015/10 (1)

Thromboplastin L
Instructions for use

en

INTENDED PURPOSE

The Thromboplastin L kit is intended for carrying out clot based haemostasis assays.

The first standardised one-stage prothrombin time test was developed by Dr. Armand Quick in 1935. It has now become the basic coagulation screening test for the diagnosis of congenital and acquired deficiencies of clotting factors from the extrinsic pathway (factors II, V, VII and X)[1,2]. It is also used for the induction and monitoring of oral anticoagulant therapy[3,4] and can be used to assess the protein synthesis capability of the liver in chronic or acute hepatic disorders.
Thromboplastin L is of rabbit brain origin but resembles human preparations in its low International Sensitivity Index (ISI). The ISI of Thromboplastin L is approximately 1.1 and is calibrated against the WHO international reference preparation[5]. Thromboplastin L is particularly suited to the monitoring of oral anticoagulant therapy and, in conjunction with the appropriate factor deficient plasma, the measurement of factor activity in the extrinsic pathway. Tissue thromboplastin, in the presence of calcium ions, is an activator which initiates the extrinsic pathway of coagulation. When a mixture of tissue thromboplastin and calcium ions is added to normal citrated plasma, the clotting mechanism is activated, leading to a fibrin clot. If a deficiency exists within the extrinsic pathway, the time required for clot formation will be prolonged depending on the severity of the deficiency.

WARNINGS AND PRECAUTIONS

The reagents contained in this kit are for in vitro diagnostic use only – DO NOT INGEST. Wear appropriate personal protective equipment when handling all kit components. Refer to the product safety declaration for the link to appropriate hazard and precautionary statements where applicable. Dispose of components in accordance with local regulations.

COMPOSITION

Composition	Content	Description	Preparation
Thromboplastin L	2 x 5 mL (REF 5265HL) 8 x 5 mL (REF 5265L) 10 x 10 mL (REF 5267L)	Liquid Rabbit Brain Thromboplastin containing Calcium Chloride, stabilisers and preservatives.	The liquid, calcified thromboplastin is ready-for-use. No further calcium is required to carry out standard PT Assays. The contents of the vial should be mixed well before use. (5 minutes on roller).

Each kit contains Instructions For Use.
Each kit contains lot specific reference values insert.

ITEMS REQUIRED BUT NOT PROVIDED

The below products can be used in conjunction with Thromboplastin L:

REF 5519 ISI Calibrant Plasma Set
REF 5490 INR Reference Set

STORAGE, SHELF-LIFE AND STABILITY

Unopened reagents are stable until the given expiry date when stored under conditions indicated on the vial or kit label.

Thromboplastin L: Opened vials are stable for 2 months at 2...8°C, 5 days at 15°C (on-board Sysmex CA-1500) and 6 hours at 37°C (on-board AC-4 including reagent container and cap). A shift-use stability of 7 days (Sysmex CA-1500) can be achieved.
DO NOT FREEZE. Large clumps of particles or changes in expected values may indicate product deterioration.

SAMPLE COLLECTION AND PREPARATION

Plastic or siliconised glass should be used throughout. Blood (9 parts) should be collected into 3.2% or 3.8% sodium citrate anticoagulant (1 part). Separate plasma after centrifugation at 1500 x g for 15 minutes. Plasma should be kept at 18...24°C. Testing should be completed within 4 hours of sample collection, or plasma can be stored frozen at -20°C for 2 weeks or -70°C for 6 months. Thaw quickly at 37°C prior to testing. Do not keep at 37°C for more than 5 minutes[6].

PROCEDURE

For accurate INR reporting, it is recommended to determine the laboratory specific ISI of the reagent with the testing system in use. The Helena Biosciences Europe ISI Calibrant Plasma Set (REF 5519) is recommended for this purpose[7,8]. This should be performed for each new reagent batch. The Helena Biosciences Europe INR Reference Set (REF 5490) should be used to check for shifts in the local system ISI which have been noted with changes in laboratory temperature and post instrument servicing, amongst other local variations.

Manual Method

1. Mix sufficient Thromboplastin L to complete the anticipated testing for the day and incubate at 37°C for no more than 4 hours.
2. Pre-warm 0.1 mL of the test plasma at 37°C for 2 minutes.
3. Add 0.2 mL of freshly mixed thromboplastin reagent to the plasma while simultaneously starting a stopwatch.
4. Note the time for clot formation to the nearest 0.1 seconds.

Automated Method

Refer to the appropriate instrument operator manual for detailed instructions or contact Helena Biosciences Europe for instrument specific application guides.

INTERPRETATION OF RESULTS

Results should be reported to the nearest 0.1 seconds and duplicates should agree within 5% of each other. %PT values can be interpolated from the calibration graph (%PT of PT Calibration plasmas versus measured clot time), which should be a straight line when plotted on log/log graph paper.

INR values can be calculated using the following formula: INR = (PT Time Patient / Mean Normal PT Time)[ISI]

For clear guidance on the indications for and management of patients on warfarin, please refer to The British Society for Haematology for their most current edition of 'Guidelines on oral anticoagulation with warfarin'. At time of printing this is the 2011 fourth edition[9].

LIMITATIONS

The use of serial dilutions of a reference plasma for the %PT curve is not recommended as this can lead to discrepancies caused by the low fibrinogen in the reference plasma dilutions which are not reflected in patient samples having predominantly normal fibrinogen levels. Helena Biosciences Europe advise use of the 5504R %PT/Direct INR kit for this purpose.

QUALITY CONTROL

Each laboratory should establish a quality control program. Normal and abnormal control plasmas should be tested prior to each batch of patient samples, to ensure satisfactory instrument and operator performance. If controls do not perform as expected, patient results should be considered invalid.
Helena Biosciences Europe supplies the following controls available for use with this product:

REF 5186 Routine Control N
REF 5187 Routine Control A
REF 5183 Routine Control SA
REF 5490 INR Reference Set

REFERENCE VALUES

Reference values can vary between laboratories depending on the techniques and systems in use. For this reason each laboratory should establish its own reference ranges. This is particularly important for local ISI calibration. Using the Sysmex series of instruments, normal values ranging from 11.50 - 14.60 seconds, 0.930 - 1.160 INR, 79.10 - 112.80 %PT are typical.

PERFORMANCE CHARACTERISTICS

The following performance characteristics have been determined by Helena Biosciences Europe or their representatives using a Sysmex CA-1500 coagulation instrument. Each laboratory should establish its own performance data.

Reproducibility

Sample	Routine Control N		Routine Control A		Routine Control SA	
	SD	CV (%)	SD	CV (%)	SD	CV (%)
Repeatability	0.07	0.59	0.24	1.09	0.45	1.11
Between-run	0.10	0.83	0.16	0.75	0.49	1.20
Between-day	0.04	0.32	0.06	0.27	0.25	0.62
Within-device / Laboratory	0.12	1.07	0.29	1.35	0.72	1.75

Interferences

Helena Thromboplastin L is insensitive to Heparin levels of up to 2 U/mL. Using a 5% interference threshold, there is no significant interference from Haemoglobin at concentrations up to 10 g/L. Using a 5% interference threshold, there is no significant interference from Bilirubin at concentrations up to 0.5 g/L for Thromboplastin L. Lipid interference testing demonstrates that lipid levels do not directly affect the clot time of the reagent up to 3.75g/L. Lipid concentrations in excess of this prevent clot detection.

Method Comparison

Comparison of clot time in seconds and INR values were determined using Thromboplastin L and Thromboplastin LI on 268 samples. The following correlations were obtained:

Thromboplastin L (Seconds) = 0.9911x + 0.1038	r^2 = 0.9941	n = 268
Thromboplastin L (INR) = 0.9853x + 0.0261	r^2 = 0.9900	n = 268

BIBLIOGRAPHY

1. Quick AJ (1935) A Study of the Coagulation Defect in Hemophilia and Jaundice, *Am. J. Med. Sci.* 190: 501
2. Biggs R (1976) Human Blood Coagulation, Haemostasis and Thrombosis, 2nd Edition, Blackwell Scientific Publications, London.
3. Hirsh J, Poller L, Deykin D, Levine J, Dalen JE (1989) Optimal Therapeutic Range for Oral Anticoagulants, *Chest*, 95: 5S-11S.
4. Poller L (1986) Laboratory Control of Anticoagulant Therapy, *Sem. Thromb. Haemostasis*, 12: 13-19.
5. World Health Organisation (1984) Expert Committee on Biological Standards, *Technical Series*, 700: 19.
6. Clinical and Laboratory Standards Institute (2008) Collection, Transport and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Haemostasis Assays: Approved Guideline, 5th edn. CLSI H21-A5.
7. Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K (1995) The value of plasma calibrants in correcting coagulometer effects on International Normalised Ratios (INR): An international multicentre study, *Amer. J. Clin. Pathol*, 103: 358-365.
8. Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K (1995) A comparison of lyophilised artificially depleted plasmas and lyophilised plasmas from warfarin treated patients in correcting for coagulometer effects on International Normalised Ratios, *Amer. J. Clin. Pathol*, 103: 366-371.
9. Keeling D (2011) Guidelines on Oral Anticoagulation with warfarin. Forth Edition, *British Journal of Haematology*, 154(3): 311-324.

Thromboplastin L
Fiche technique

fr

UTILISATION

Le kit Thromboplastin L est destiné à la réalisation des analyses de l'hémostase basées sur la formation de caillots.

La première méthode de détermination standardisée du temps de prothrombine en une étape a été développée en 1935 par le Dr. Armand Quick. Cette méthode de Quick constitue désormais l'analyse de base de la coagulation servant à diagnostiquer des anomalies des facteurs de coagulation, congénitales ou acquises, à partir de la voie extrinsèque (facteurs II, V, VII et X)[1,2]. Elle sert aussi à l'induction et au monitorage des thérapies avec anticoagulants oraux[3,4] et elle peut être utilisée pour évaluer la capacité de synthèse des protéines du foie chez les patients souffrants de troubles hépatiques chroniques ou aigus.
Le Thromboplastin L provient de cerveaux de lapin mais il ressemble au BCT humain en raison de son indice de sensibilité international (ISI) faible. L'ISI du Thromboplastin L est d'environ 1,1 et est étalonné en comparaison avec la préparation internationale de référence de l'OMS[5]. Le Thromboplastin L convient tout particulièrement au monitorage des thérapies avec anticoagulants oraux et, utilisé conjointement au plasma carencé en un facteur approprié, à la détermination de l'activité du facteur de la voie extrinsèque. La thromboplastine tissulaire, en présence d'ions calcium, est un activateur qui démarre la voie extrinsèque de la coagulation. Quand un mélange de thromboplastine tissulaire et d'ions calcium est ajouté à un plasma citraté normal, le processus de coagulation, qui doit conduire à la production d'un caillot fibreux, s'active. Si la voie extrinsèque présente une anomalie, le temps nécessaire à la formation du caillot est allongé suivant la gravité du trouble de la coagulation.

AVERTISSEMENTS ET PRÉCAUTIONS

Les réactifs du kit sont à usage diagnostique *in vitro* uniquement – NE PAS INGERER. Porter un équipement de protection individuelle approprié lors de la manipulation de tous les composants du kit. Consulter la fiche de données de sécurité du produit pour obtenir le lien vers les phrases de risque et les conseils de prudence le cas échéant. Éliminer les composants conformément aux réglementations locales.

COMPOSITION

Composant	Contient	Description	Préparation
Thromboplastin L	2 x 5 mL (REF 5265HL) 8 x 5 mL (REF 5265L) 10 x 10 mL (REF 5267L)	Thromboplastine liquide de cerveau de lapin contenant du chlorure de calcium, des stabilisateurs et des conservateurs.	La thromboplastine liquide calcifiée est prête à l'emploi. Aucun calcium supplémentaire n'est nécessaire pour réaliser des déterminations standard du TP. Le contenu du flacon doit être bien mélangé avant utilisation (5 minutes sur un mélangeur à rouleaux).

Chaque kit contient une fiche technique.
Chaque kit contient valeurs de référence spécifiques du lot.

MATÉRIEL NÉCESSAIRE NON FOURNI

Les produits ci-dessous peuvent être utilisés en conjonction avec le Thromboplastin L :

REF 5519 ISI Calibrant Plasma Set
REF 5490 INR Reference Set

CONSERVATION, DURÉE DE VIE UTILE ET STABILITÉ

Les flacons de réactif non ouverts sont stables jusqu'à la date de péremption indiquée s'ils sont conservés dans les conditions indiquées sur l'étiquette du kit ou du flacon.

Thromboplastin L: Les flacons ouverts sont stables pendant 2 mois à 2 °C – 8 °C, pendant 5 jours à 15 °C (à bord du Sysmex CA-1500) et pendant 6 heures à 37 °C (à bord de l'AC-4, récipient de réactif et capuchon inclus). Il est possible d'obtenir une stabilité de période de travail de 7 jours (Sysmex CA-1500).
NE PAS CONGELER. La présence de d'amas de particules ou un écart par rapport aux valeurs prévues indique une détérioration du produit.

PRÉLÈVEMENT ET PRÉPARATION DES ÉCHANTILLONS

Utiliser tout au long du prélèvement du plastique ou du verre siliconé. Mélanger 9 volumes de sang et 1 volume de citrate de sodium à 3,2% ou 3,8%. Séparer le plasma après centrifugation à 1500 x g pendant 15 minutes. Conserver le plasma entre 18 – 24°C. L'analyse doit être terminée dans les 4 heures suivant le prélèvement de l'échantillon ; sinon, il est possible de congeler le plasma 2 semaines à -20°C ou 6 mois à -70°C. Décongeler rapidement à 37°C avant de réaliser l'analyse. Ne pas laisser à 37°C plus de 5 minutes[6].

PROCÉDURE

Pour obtenir un RNI (rapport normalisé international) précis, il est recommandé à chaque laboratoire de déterminer l'ISI spécifique du réactif avec le système d'analyse utilisé. Il est conseillé d'utiliser le ISI Calibrant Plasma Set Helena Biosciences Europe (REF 5519) pour cela[7,8]. Cette opération doit être réalisée pour chaque nouveau lot de réactif. Le kit RNI de référence Helena Biosciences Europe (REF 5490) doit être utilisé pour vérifier l'existence d'un décalage de l'ISI du système local déterminé en raison d'une variation de la température du laboratoire, suite à une opération de maintenance réalisée sur l'instrument ou toute autre variable locale.

Méthode Manuelle

1. Mélanger du Thromboplastin L en quantité suffisante pour réaliser les analyses prévues dans la journée et incuber à 37 °C pendant 4 heures au maximum.
2. Préchauffer 0,1 mL de plasma à 37°C pendant 2 minutes.
3. Ajouter 0,2 mL de réactif de thromboplastine fraîchement mélangé au plasma et démarrer à ce moment un chronomètre.
4. Relever le temps de formation du caillot en arrondissant au dixième de seconde.

Méthodes Automatisées

Consulter le manuel d'utilisation de l'instrument approprié pour obtenir des instructions détaillées ou contacter Helena Biosciences Europe pour obtenir des notes d'application spécifiques à l'instrument.

INTERPRÉTATION DES RÉSULTATS

Les résultats doivent être indiqués en arrondissant au dixième de seconde et l'écart maximal entre eux est de 5%. Il est possible d'interpoler les valeurs de %TP à partir de la courbe d'étalonnage (%TP des plasmas d'étalonnage du TP par rapport au temps de coagulation mesuré), qui doit correspondre à une ligne droite quand elle est représentée sur du papier logarithmique.

La formule suivante permet de calculer les valeurs du RNI: RNI = (Temps TP patient / Temps TP moyen normal)[ISI]

Pour obtenir des informations claires quant aux indications et à la prise en charge des patients sous warfarine, consulter la British Society for Haematology pour obtenir la dernière édition des Guidelines on oral anticoagulation with warfarin (Recommandations relatives à l'anticoagulothérapie orale avec la warfarine). Au moment de l'impression du présent document, il s'agit de la quatrième édition de 2011[9].

LIMITES

Il est déconseillé de réaliser des dilutions du plasma de référence pour la courbe de %TP, car cela risquerait d'entraîner des divergences dues au faible taux de fibrinogène présent dans les dilutions du plasma de référence, ce qui ne serait pas représentatif des échantillons patients qui ont principalement des taux de fibrinogène normaux. Helena Biosciences Europe conseille l'utilisation du kit 5504R %PT/Direct INR dans ce but.

CONTRÔLE QUALITÉ

Chaque laboratoire doit établir un programme de contrôle qualité. Les plasmas de contrôle, normaux et anormaux, doivent être testés avant chaque lot d'échantillons patients afin de s'assurer que l'instrument et l'opérateur offrent des performances satisfaisantes. Si les contrôles ne donnent pas les résultats prévus, les résultats du patient doivent être considérés comme non valables.
Helena Biosciences Europe distribue les contrôles suivants à utiliser avec ce produit:

REF 5186 Routine Control N
REF 5187 Routine Control A
REF 5183 Routine Control SA
REF 5490 INR Reference Set

VALEURS DE RÉFÉRENCE

Les valeurs de référence peuvent varier d'un laboratoire à l'autre suivant les techniques et les systèmes utilisés. C'est pour cette raison qu'il appartient à chaque laboratoire de déterminer ses propres plages de référence. Ceci est particulièrement important pour l'étalonnage de l'ISI local. Avec les instruments de la série Sysmex, l'intervalle type des valeurs normales est de 11,50 - 14,60 secondes; 0,930 - 1,160 INR, 79,10 - 112,80 %PT.

CARACTÉRISTIQUES DE PERFORMANCES

Helena Biosciences Europe ou ses mandataires ont déterminé les caractéristiques de performance suivantes en utilisant un instrument de coagulation Sysmex CA-1500. Chaque laboratoire doit établir ses propres données de performance.

Reproductibilité

Échantillon	Routine Control N		Routine Control A		Routine Control SA	
	SD	CV (%)	SD	CV (%)	SD	CV (%)
Répétabilité	0,07	0,59	0,24	1,09	0,45	1,11
Inter-séries	0,10	0,83	0,15	0,75	0,49	1,20
Inter-jours	0,04	0,32	0,06	0,27	0,25	0,62
Intra-dispositif/laboratoire	0,12	1,07	0,29	1,35	0,72	1,75

Interférences

Thromboplastin L (ISI faible) d'Helena ne présente pas d'interférences avec un taux d'héparine jusqu'à 2 U/mL. En utilisant un seuil d'interférence de 5 %, il n'y a pas d'interférences significatives de l'hémoglobine à une concentration jusqu'à 10 g/L. En utilisant un seuil d'interférence de 5 %, il n'y a pas d'interférences significatives de la bilirubine à une concentration jusqu'à 0,5 g/L pour le Thromboplastin L. Une évaluation de l'interférence des lipides montre que les taux de lipides n'affectent pas le temps de coagulation du réactif jusqu'à 3,75 g/L. Une concentration en lipides dépassant cette limite empêche la détection du caillot.

Comparaison de la méthode

Des comparaisons du temps de coagulation en secondes et en valeurs de RNI ont été déterminées en utilisant les produits Thromboplastin L et Thromboplastin LI avec 268 échantillons. Les corrélations suivantes ont été obtenues:

Thromboplastin L (seconds) = 0,9911x + 0,1038	r^2 = 0,9941	n = 268
Thromboplastin L (INR) = 0,9853x + 0,0261	r^2 = 0,9900	n = 268

BIBLIOGRAPHIE

1. Quick AJ (1935) A Study of the Coagulation Defect in Hemophilia and Jaundice, *Am. J. Med. Sci*, 190: 501.
2. Biggs R (1976) Human Blood Coagulation, Haemostasis and Thrombosis, 2nd Edition, Blackwell Scientific Publications, London.
3. Hirsh J, Poller L, Deykin D, Levine J, Dalen JE (1989) Optimal Therapeutic Range for Oral Anticoagulants, *Chest*, 95: 5S-11S.
4. Poller L (1986) Laboratory Control of Anticoagulant Therapy, *Sem. Thromb. Haemostasis*, 12: 13-19.
5. World Health Organisation (1984) Expert Committee on Biological Standards, *Technical Series*, 700: 19.
6. Clinical and Laboratory Standards Institute (2008) Collection, Transport and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Haemostasis Assays: Approved Guideline, 5th edn. CLSI H21-A5.
7. Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K (1995) The value of plasma calibrants in correcting coagulometer effects on International Normalised Ratios (INR): An international multicentre study, *Amer. J. Clin. Pathol*, 103: 358-365.
8. Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K (1995) A comparison of lyophilised artificially depleted plasmas and lyophilised plasmas from warfarin treated patients in correcting for coagulometer effects on International Normalised Ratios, *Amer. J. Clin. Pathol*, 103: 366-371.
9. Keeling D (2011) Guidelines on Oral Anticoagulation with warfarin. Forth Edition, *British Journal of Haematology*, 154(3): 311-324.

Thromboplastin L
Anleitung

VERWENDUNGSZWECK

Das Thromboplastin L Kit ist für koagulometrische Gerinnungstests vorgesehen.

Die erste standardisierte Prothrombinzeit als Einstufen-Test wurde 1935 von Dr. Armand Quick entwickelt. Mittlerweile ist der Standard-Screeningtest in der Gerinnung zur Diagnose eines vererbten oder erworbenen Gerinnungsfaktormangels des extrinsischen Systems (Faktor II, V, VII und X)[1,2]. Er wird auch zur Einstellung und Überwachung von oralen Antikoagulanztherapien[3,4] verwendet und kann bei chronischen und akuten Lebererkrankungen zur Beurteilung der Funktionsfähigkeit der Leber bei der Proteinsynthese herangezogen werden.
Thromboplastin L wird aus Kaninchenhirn gewonnen, ähnelt aber mit seinem niedrigen „International Sensitivity Index" (ISI) humaner Blutgerinnungszeit. Der ISI von Thromboplastin L liegt bei ca. 1,1 und ist gegen WHO „International Reference Preparation" kalibriert[5]. Thromboplastin L ist besonders für die Überwachung oraler Antikoagulanztherapien geeignet und, in Verbindung mit dem entsprechenden Faktor-Mangelplasma, für die Messung von Faktoraktivitäten im extrinsischen System. Gewebethromboplastin ist in Anwesenheit von Calcium-Ionen ein Aktivator, der das extrinsische Gerinnungssystem auslöst. Gibt man eine Mischung von Gewebethromboplastin und Calcium-Ionen zu normalem Citratplasma, wird die Gerinnungskaskade aktiviert und es bildet sich ein Fibringerinnsel. Besteht innerhalb des extrinsischen Systems ein Mangel, verlängert sich, je nach Schwere dieses Mangels, die Zeit bis zur Ausbildung eines Gerinnsels.

WARNHINWEISE UND VORSICHTSMASSNAHMEN

Die in diesem Kit enthaltenen Reagenzien sind ausschließlich für die Verwendung von in-vitro-Diagnosen vorgesehen. NICHT VERSCHLUCKEN. Tragen Sie beim Umgang mit sämtlichen Komponenten des Kits geeignete Schutzausrüstung. Beachten Sie gegebenenfalls die Verweise auf entsprechende Gefahren- und Vorbeugeerklärungen in der Produktsicherheitserklärung. Entsorgen Sie die Komponenten gemäß den örtlichen Vorschriften.

ZUSAMMENSETZUNG

Komponente	Inhalt	Beschreibung	Vorbereitung
Thromboplastin L	2 x 5 mL (REF 5265HL) 8 x 5 mL (REF 5265L) 10 x 10 mL (REF 5267L)	Flüssiges Thromboplastin aus Hasenhirn mit Calciumchlorid, Stabilisatoren und Konservierungsstoffen	Das flüssige, kalzifizierte Thromboplastin ist einsatzbereit. Für die Durchführung von standardmäßigen PT-Analysen ist kein zusätzliches Calcium erforderlich. Der Inhalt der Ampulle muss vor der Verwendung gut gemischt werden (5 Minuten auf dem Walzenmischer).

Jedes Kit enthält eine Gebrauchsanweisung.
Jedes Kit enthält chargenspezifischen Referenzwerten.

ERFORDERLICHE, ABER NICHT MITGELIEFERTE ARTIKEL

Die folgenden Produkte können in Kombination mit Thromboplastin L verwendet werden:

REF 5519 ISI Calibrant Plasma Set
REF 5490 INR Reference Set

LAGERUNG, HALTBARKEIT UND STABILITÄT

Ungeöffnete Reagenzien sind unter den auf Verpackung oder Fläschchen angegebenen Lagerbedingungen bis zum aufgedruckten Verfallsdatum stabil.

Thromboplastin L: Offene Ampullen sind 2 Monate bei 2 – 8°C, 5 Tage bei 15°C (im Sysmex CA-1500) und 6 Stunden bei 37°C (im AC-4 mit Reagenzbehälter und Deckel) stabil. Eine Stabilität von 7 Tagen im Schichtbetrieb (Sysmex CA-1500) kann erreicht werden.
NICHT EINFRIEREN. Große Verklumpungen oder Veränderungen in den Erwartungswerten können auf einen Verfall des Produkts hinweisen.

PROBENENTNAHME UND VORBEREITUNG

Nur Plastik- oder Silikonglas verwenden. Blut (9 Teile) sollte in 3,2% oder 3,8% Natriumcitrat als Antikoagulanz (1 Teil) entnommen werden. 15 Minuten bei 1500 g zentrifugieren und Plasma abpipettieren. Plasma bei 18 – 24°C lagern. Plasma sollte innerhalb von 4 Stunden verarbeitet oder tief gefroren bei -20°C für 2 Wochen oder -70°C für 6 Monate gelagert werden. Vor dem Testen schnell bei 37°C auftauen. Nicht länger als 5 Minuten bei 37°C belassen[6].

VORGEHENSWEISE

Um einen korrekten INR zu erhalten, wird empfohlen, den laborspezifischen ISI für das Reagenz mit dem verwendeten Testsystem zu bestimmen. Helena Biosciences Europe empfiehlt zu diesem Zweck das Plasma-Kalibratorset REF 5519[7,8]. Das sollte mit jeder neuen Reagenzien-Charge durchgeführt werden. Das Helena Biosciences Europe INR Reference Set (REF 5490) dient zur Überprüfung von Verschiebungen im ISI vor Ort, die unter anderem durch Veränderungen der Labortemperatur und nach Wartungsarbeiten an den Geräten festgestellt worden sind.

Manuelle Methode

1. Mischen Sie eine ausreichende Menge von Thromboplastin L an, um die für den Tag geplanten Tests durchzuführen und inkubieren Sie es nicht länger als 4 Stunden bei 37°C.
2. 0,1 mL des zu testenden Plasmas bei 37°C 2 Minuten vorwärmen.
3. 0,2 mL des frisch zubereiteten Thromboplastin-Reagenz zum Plasma pipettieren, dabei gleichzeitig Stoppuhr drücken.
4. Die Zeit bis zur Gerinnselbildung bis auf 0,1 Sekunden genau stoppen.

Automatisierte Methoden

Siehe die Bedienungsanleitung des entsprechenden Geräts für genaue Anweisungen oder wenden Sie sich an Helena Biosciences Europe für spezielle anwendungstechnische Hinweise.

INTERPRETATION DER ERGEBNISSE

Ergebnisse sollten bis auf 0,1 Sekunden genau gemessen werden und Doppelbestimmungen nicht mehr als 5% abweichen. %TPZ-Werte können ausgehend von der Kalibratorkurve interpoliert werden (% TPZ des TP-Kalibrationsplasmas zu gemessener Gerinnungszeit) und sollten auf doppeltlogarithmischem Millimeterpapier eine gerade Linie ergeben.

INR-Werte können anhand der folgenden Formel berechnet werden: INR = (PT Zeit Patient / Mittelwert normale TPZ)[ISI]

Für klare Leitlinien zu den Indikationen für und der Versorgung von Patienten unter Warfarin siehe die aktuelle Ausgabe der "Guidelines on oral anticoagulation with warfarin" der British Society for Haematology. Zum Zeitpunkt der Drucklegung ist das die 4. Ausgabe 2011[9].

EINSCHRÄNKUNGEN

Die Verwendung einer Serienverdünnung von Referenzplasma ist für die %PT-Kurve nicht zu empfehlen, da dies zu Diskrepanzen aufgrund von niedrigem Fibrinogen in den Referenzplasma-Verdünnungen führen kann, das nicht den Patientenproben entspricht, die in der Regel normale Fibrinogen-Werte haben. Helena Biosciences Europe empfiehlt zu diesem Zweck das Set 5504R %PT/Direct INR einzusetzen.

QUALITÄTSKONTROLLE

Jedes Labor muss für eine eigene Qualitätskontrolle sorgen. Vor jeder Testreihe mit Patientenproben müssen normale und pathologische Kontrollplasmen getestet werden, um eine zufriedenstellende Geräteleistung und Bedienung zu gewährleisten. Liegen die Kontrollen außerhalb des Normbereichs, sind die Patientenergebnisse nicht zu verwenden.
In Verbindung mit diesem Produkt bietet Helena Biosciences Europe die folgenden Kontrollen an:

REF 5186 Routine Control N
REF 5187 Routine Control A
REF 5183 Routine Control SA
REF 5490 INR Reference Set

REFERENZWERTE

Referenzwerte können je nach Technik und verwendetem System von Labor zu Labor unterschiedlich sein. Aus diesem Grund sollte jedes Labor seine eigenen Referenzwertbereiche erstellen. Dieses ist besonders für die ISI-Kalibrierung vor Ort wichtig. Mit der Instrumentenreihe Sysmex liegen die typischen Normalwerte zwischen 11,50 - 14,60 Sekunden, 0,930 - 1,160 INR, 79,10 - 112,80 %PT.

LEISTUNGSMERKMALE

Die folgenden Leistungseigenschaften wurden von Helena Biosciences Europe oder in ihrem Auftrag mit einem Sysmex CA-1500 Gerinnungsgerät ermittelt. Jedes Labor muss seine eigenen Werte ermitteln.

Reproduzierbarkeit

Probe	Routine Control N		Routine Control A		Routine Control SA	
	SD	CV (%)	SD	CV (%)	SD	CV (%)
Wiederholbarkeit	0,07	0,59	0,24	1,09	0,45	1,11
Bei verschiedenen Analysen	0,10	0,83	0,16	0,75	0,49	1,20
An verschiedenen Tagen	0,04	0,32	0,06	0,27	0,25	0,62
Selbes Gerät/Labor	0,12	1,07	0,29	1,35	0,72	1,75

Störungen

Helena Thromboplastin L ist unempfindlich gegenüber Heparinwerten bis zu 2 Einheiten/mL. Mit einer Störschwelle von 5 % gibt es keine besondere Interferenz durch Hämoglobin bei Konzentrationen von bis zu 10 g/l. Mit einer Störschwelle von 5 % gibt es keine besondere Interferenz durch Bilirubin bei Konzentrationen von bis zu 0,5 g/l bei Thromboplastin L. Lipidinterferenztests zeigen, dass die Lipidmenge die Gerinnungszeit des Reagenz bis 3,7 g/l nicht direkt beeinflusst. Höhere Lipidkonzentrationen verhindern die Gerinnungserkennung.

Methodenvergleich

Thromboplastin L und Thromboplastin LI wurden an 268 Proben angewandt. Dabei wurden die Gerinnungszeit in Sekunden verglichen und die INR-Werte bestimmt. Es ergaben sich folgende Korrelationen:

Thromboplastin L (sekunden) = 0,9911x + 0,1038	r^2 = 0,9941	n = 268
Thromboplastin L (INR) = 0,9853x + 0,0261	r^2 = 0,9900	n = 268

LITERATURVERZEICHNIS

1. Quick AJ (1935) A Study of the Coagulation Defect in Hemophilia and Jaundice, *Am. J. Med. Sci*, 190: 501.
2. Biggs R (1976) Human Blood Coagulation, Haemostasis and Thrombosis, 2nd Edition, Blackwell Scientific Publications, London.
3. Hirsh J, Poller L, Deykin D, Levine J, Dalen JE (1989) Optimal Therapeutic Range for Oral Anticoagulants, *Chest*, 95: 5S-11S.
4. Poller L (1986) Laboratory Control of Anticoagulant Therapy, *Sem. Thromb. Haemostasis*, 12: 13-19.
5. World Health Organisation (1984) Expert Committee on Biological Standards, *Technical Series*, 700: 19.
6. Clinical and Laboratory Standards Institute (2008) Collection, Transport and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Haemostasis Assays: Approved Guideline, 5th edn. CLSI H21-A5.
7. Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K (1995) The value of plasma calibrants in correcting coagulometer effects on International Normalised Ratios (INR): An international multicentre study, *Amer. J. Clin. Pathol*, 103: 358-365.
8. Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K (1995) A comparison of lyophilised artificially depleted plasmas and lyophilised plasmas from warfarin treated patients in correcting for coagulometer effects on International Normalised Ratios, *Amer. J. Clin. Pathol*, 103: 366-371.
9. Keeling D (2011) Guidelines on Oral Anticoagulation with warfarin. Forth Edition, *British Journal of Haematology*, 154(3): 311-324.

SOCIETATEA CU RĂSPUNDERE LIMITATĂ
S.R.L.
"GEC-MLD"
REPUBLICA MOLDOVA, MUN. CHIȘINĂU
IDNO [illegible]

Lloyd's Register
LRQA

CERTIFICATE OF APPROVAL

This is to certify that the Quality Management System of:

Avantor Performance Materials Poland S.A.
ul. Sowińskiego 11
44-101 Gliwice, Poland

has been approved by Lloyd's Register Quality Assurance
to the following Quality Management System Standards:

ISO 13485:2012

The Quality Management System is applicable to:

Production, sales and supply of high purity reagents and kits for in vitro diagnostics.

Approval
Certificate No:
GDK6037065

Original Approval:	21st April 2016
Current Certificate:	21st April 2016
Certificate Expiry:	20th April 2019

Issued by: Lloyd's Register (Polska) sp. z o.o.
for and on behalf of Lloyd's Register Quality Assurance Limited

UKAS
MANAGEMENT
SYSTEMS
001

Lloyd's Register (Polska) sp. z o.o., al. Zwycięstwa 13a, 80-219 Gdańsk, KRS 0000117768
for and on behalf of LRQA Ltd 1 Trinity Park, Bickenhill Lane, Birmingham, B37 7ES, United Kingdom

Avantor Performance Materials Poland Spółka Akcyjna
ul. Sowińskiego 11
44-101 Gliwice, Poland
Tel.: +48 32 239 20 00
Fax: +48 32 239 23 70
e-mail: avantor.pl@avantormaterials.com
www.poch.com.pl
www.avantormaterials.com

Declaration of conformity

Avantor Performance Materials Poland S.A. who is an established manufacturer of reagents and products for diagnostic in vitro located at:

Sowińskiego 11 Street
44-101, Gliwice
Poland

Herewith declares the following:
Reagents mentioned in attached list are labeled with J.T.Baker label, comply with the In Vitro Diagnostic Medical Devices Directive 98/79/EC and the requirements of ISO 13485 Standard.
This declaration is the basic for CE marking of the In Vitro Diagnostic Medical Devices.
The products are not part of List A and List B of Annex II of the IVD Directive 98/79/EC but are subject to self registration.
This declaration is valid for all the IVD medical devices described above and which are placed on the market by ourselves on or after the date hereof and which bear the CE marking.

Gliwice, Poland.
June 14, 2016

Anna Szuba
Quality Director

NIP: 631-010-13-07
Sąd Rejonowy w Gliwicach, X Wydział Gospodarczy KRS nr 0000010108
Wysokość kapitału zakładowego: 2 360 793,00 zł., w całości opłacony

Avantor Performance Materials Poland Spółka Akcyjna
ul. Sowińskiego 11
44-101 Gliwice, Poland
Tel.: +48 32 239 20 00
Fax: +48 32 239 23 70
e-mail: avantor.pl@avantormaterials.com
www.poch.com.pl
www.avantormaterials.com

Deklaracja zgodności WE

Avantor Performance Materials Poland S.A. producent odczynników do diagnostyki in vitro zlokalizowany:

ul. Sowińskiego 11
44-101, Gliwice
Polska

Deklaruje zgodność odczynników wymienionych w załączonej liście oznakowanych etykietą J.T.Baker z wymaganiami Dyrektywy 98/79/WE Parlamentu Europejskiego i Rady w sprawie wyrobów medycznych używanych do diagnostyki in vitro oraz wymaganiami normy ISO 13485.
Powyższe odczynniki są oznakowane etykietą J.T.Baker i posiadają znaki CE na etykiecie.
Produkty nie są częścią wykazu A i wykazu B załącznika II Dyrektywy dla wyrobów medycznych do diagnostyki in vitro z Dyrektywy 98/79/WE Parlamentu Europejskiego i Rady, ale podlegają rejestracji.
Deklaracja obowiązuje dla wszystkich wyrobów medycznych do diagnostyki in vitro opisanych powyżej oraz wprowadzonych na rynek i posiadających oznakowanie CE.

Gliwice, Polska.
Czerwiec 14, 2016

Anna Szuba
Dyrektor Jakości

NIP: 631-010-13-07
Sąd Rejonowy w Gliwicach, X Wydział Gospodarczy KRS nr 0000010108
Wysokość kapitału zakładowego: 2 360 793,00 zł., w całości opłacony

Trademarks are owned by Avantor Performance Materials, Inc. or its affiliates unless otherwise noted
© 2014 Avantor Performance Materials, Inc.

Product	Product Number	Pack Size
H32 3-Part Differential	2983	1 unit
Diluid™ 100 Plus	3961	20 L
Diluid™ 22	2990.9010PC	10 L
Diluid™ 610	3969	20 L
Diluid™ Abacus	3430.9020	20 L
	3430.9010	10 L
Diluid™ AC 900	3996	20 L
Diluid™ APR	3476.9020PC	20 L
Diluid™ Azide free	3957	20 L
Diluid™ III Diff	3963	20 L
Diluid™ Erma	3459.9020	20 L
Diluid™ Mindray	3439.9020PC	20 L
Diluid™ NR	3483.9020PC	20 L
Diluid™ Ruby	2987.9020PC	20 L
Diluid™/Sheath 3200-4000	3832.9020	20 L
Diluid™ ST1600/2000	3976	20 L
Sheath D	3495.9010PC	10 L
Sheath Fluid 3000/3500	3471.9020PC	20 L
CN-free Lyse Diff AC 900	3998	5 L
CyMet™ 22	2986.0500PE	500 ml
CyMet™ 3000	3469.9010PC	10 L
CyMet™ 3200 CN free	3823.1000	1 L
CyMet™ 3500	3839.5000PC	5 L
CyMet™ 3500 CN free	3825	5 L
CyMet™ 610 CN free	3970	10 L
	3977	5 L
CyMet™ Abacus CN free	3431.1000	1 L
CyMet™ APR Baso II	3479.1000PE	1 L
CyMet™ APR CN free	3417.0500PE	500 ml
CyMet™ APR EO	3478.1000PE	1 L
CyMet™ ASA	2950.2500PE	3.8 L
CyMet™ ASB	2951.0250PE	380 ml
CyMet™ AS CN free	2952.9010PC	10 L
CyMet™ BS3 CN free	2982.0500PE	500 ml
CyMet™ III Diff	3964	5 L
	3968	1 L
CyMet™ III Diff CN free	3511.1000	1 L
CyMet™ Erma	3416.0500	500 ml
CyMet™ H20	3853.1000	1 L
CyMet™ KX CN Free	3425.0500	500 ml
CyMet™ Micro	3852.1000	1 L
CyMet™ Micro CN free	3863.1000	1 L micros
CyMet™ Mindray CN Free	3440.0500PE	500 ml
CyMet™ NR III	3484.1000PE	1 L
CyMet™ NR III CN Free	3486.1000PE	1 L
CyMet™ NR V	3485.1000PE	1 L
CyMet™ Ruby CN Free	2988.5000PC	5 L
CyMet™ ST 1600/2000 CN free	3759.5000	5 L
LeucoLyse	3475.5000PC	5 L
LeucoLyse Ruby	2989.5000PC	5 L
Blankrid Solution 1600/2000	3947	20 L
DetectoTerge™	3763	5 L
	3766	1 L
DetectoTerge™ BS	2970.0900PE	900 ml
ProClean™	3900	5 L
	3768.1000	1 L micros
ProClean™ Abacus	3432.5000	5 L
	3432.1000PE	1 L

ProClean™ CD	3902.0100PE	100 ml
ProClean™ Extra	3862.5000	5 L
	3867.1000PE	1 L micros
ProClean™ Plus	3901	100 ml
Rinse Mindray	3442.5000PE	5 L
8-Parameter Control L/N/H	3427/3428/3429	2.5 ml
	3463/3464/3465	2.5 ml
8-Parameter Control L+N+H	3746	3 x 2.5 ml
8-Parameter Control 4xN	3747	4 x 2.5 ml
8-Parameter Control 1xL+4xN+1xH	3751	6 x 2.5 ml
8-Parameter Control extended L/N/H	3633/3634/3635	2.5 ml
3-Diff Control L/N/H	3433/3434/3435	2.5 ml
	3502/3503/3504	4.5 ml
3-Diff Control 4xL	3466	4 x 2.5 ml
3-Diff Control 4xN	3467	4 x 2.5 ml
3-Diff Control 4xH	3468	4 x 2.5 ml
3-Diff Control extented L/N/H	3421/3422/3423	2.5 ml
BC-Diff 5 Control L/N/H	3613/3614/3615	3.0 ml
CD-Diff Control L/N/H	3452/3453/3454	3.0 ml
CD-Diff Control 2xL+2xN+2xH	3838	6 x 3.0 ml
K-Diff Control L/N/H	3455/3456/3457	2.5 ml
Platelet Control- Extended value	3424	5 x 3.0 ml
WBC Reduced RBC L/H	3698/3699	3.0 ml
XE-Diff Control L/N/H	3731/3732/3733	4.5 ml
Cervix Spray Fixative	3869.1200	12 x 125 ml
10% v/v Buffered Formaldehyde (4% w/v)	3933.1000	1 L
10% v/v Buffered Formaldehyde (4% w/v)	3933.5000PC	5 L
10% v/v Buffered Formaldehyde (4% w/v)	3933.9010	10 L
10% v/v Buffered Formaldehyde (4% w/v)	3933.9020	20 L
UltraClear™	3905.2500PE	2.5 L
UltraClear™	3905.5000PE	5 L
UltraClear™	3905.9010PE	10 L
Eosin-Y Alcoholic	3800.1000PE	1 L
Eosin-Y Alcoholic	3800.2500PE	2.5 L
Giemsa	3856.1000	1 L
Giemsa	3856.2500	2.5 L
Hematoxylin er (Mayer)	3870.1000	1 L
Hematoxylin er (Mayer)	3870.2500	2.5 L
Hematoxylin Modified (Harris, Gill II)	3873.1000	1 L
Hematoxylin Modified (Harris, Gill II)	3873.2500	2.5 L
May-Grünwald	3855.1000	1 L
May-Grünwald	3855.2500	2.5 L
Papanicolaou 2A	3554.1000PE	1 L
Papanicolaou 2A	3554.2500PE	2.5 L
Papanicolaou 2B	3555.1000PE	1 L
Papanicolaou 2B	3555.2500PE	2.5 L
Papanicolaou 3B	3556.1000PE	1 L
Papanicolaou 3B	3556.2500PE	2.5 L
UltraKitt™	3921.0500	500 ml
UltraKitt™	3921.0600	6 x 100 ml
Mounting medium High	3882.0500	500 ml
Mounting medium Low	3883.0500	500 ml
PBS	3059	20 L
PBS	3059.9010PC	10 L

ООО "Медиклон"

МЕДИКЛОН
127276 Москва, Ботаническая ул. 35, т\ф (495) 231-2272 (499) 502-1214

ПАСПОРТ-СЕРТИФИКАТ ПРОИЗВОДИТЕЛЯ
на «Набор реагентов для определения групп крови человека систем АВО, Резус и Kell» по ТУ-9398-101-51203590-2009
(ЦОЛИКЛОН Анти-D Супер)

Наименование: Цоликлон Анти-D Супер во флаконах по 10 мл с зелеными крышками

Серия: 281411 ОКП: 93 9816

Годен: 11 декабря 2020 г. Объем серии: 10000 мл.

Единица: 100 мл Паспорт: Т-18-11-90 от 19.11.2018

Количество единиц 50

Наименование показателя	Характеристика нормы по ТУ	Результаты испытаний
1. Внешний вид	Прозрачная слегка окрашенная жидкость	Соответствует
2. Серологические свойства 2.1 Специфичность	Цоликлон Анти-D Супер не должен агглютинировать D(-) эритроциты.	Соответствует
2.2 Гемагглютинирующая способность	Четкая реакция агглютинации должна наступать в течение 30 сек. после смешивания реагента с D(+) эритроцитами	Соответствует 30 сек.
2.3 Титр	Титр Цоликлона Анти-D Супер в реакции агглютинации на плоскости с D(+) эритроцитами 1:32 Титр Цоликлона Анти-D Супер в реакции прямой агглютинации с D(+) эритроцитами в микрозоне не ниже 1:256	Соответствует 1:32 1:256

Соответствует требованиям ТУ 9398-101-51203590-2009

Заведующая лабораторией ООО «Медиклон»
М.С. Орлова

ООО "Медиклон"

МЕДИКЛОН
127276 Москва, Ботаническая ул. 35, т\ф (495) 231-2272 (499) 502-1214

ПАСПОРТ-СЕРТИФИКАТ ПРОИЗВОДИТЕЛЯ
на «Набор реагентов для определения групп крови человека систем АВО, Резус и Kell» по ТУ-9398-101-51203590-2009
(ЦОЛИКЛОНЫ Анти-А , Анти-В и Анти-АВ)

Наименование: Цоликлон Анти-АВ

Серия: 081211 ОКП: 93 9816

Годен: 1 ноября 2020 г. Объем серии: 10000 мл.

Единица: 100 мл Паспорт: Т-18-11-92 от 27.11.2018

Количество единиц 6

Наименование показателя	Характеристика нормы	Результаты испытаний
1. Внешний вид 1.1 Цоликлон анти-А 1.2 Цоликлон анти-В 1.3 Цоликлон анти-АВ	Прозрачная жидкость красного цвета Прозрачная жидкость синего цвета Прозрачная бесцветная жидкость	Соответствует
2. Серологические свойства 2.1 Специфичность	Цоликлон анти-А не должен давать агглютинации с эритроцитами групп В(III) и О(I) Цоликлон анти-В не должен давать агглютинации с эритроцитами групп А(II) и О(I)	Соответствует Соответствует
2.2 Гемагглютинирующая способность	Цоликлон анти-АВ не должен давать агглютинации с эритроцитами группы О(I) Агглютинация на плоскости эритроцитов А1 и В с соответствующими Цоликлонами должна появиться не позднее 10 сек. после смешивания	Соответствует Соответствует 10 секунд
2.3 Титр	Титр Цоликлона анти-А в реакции агглютинации на плоскости с эритроцитами группы А(II) 1:32 - 1:64 Титр Цоликлона анти-В в реакции агглютинации на плоскости с эритроцитами группы В(III) 1:64 Титр Цоликлона анти-АВ в реакции агглютинации на плоскости с эритроцитами групп А(II) 1:32 - 1:64 и В(III) 1:64	Соответствует 1:32 - 1:64 Соответствует 1:64 Соответствует 1:32 - 1:64

Цоликлон соответствует требованиям ТУ 9398-101-51203590-2009

Заведующая лабораторией ООО «Медиклон»
М.С. Орлова

ООО "Медиклон"

МЕДИКЛОН
127276 Москва, Ботаническая ул. 35, т\ф (495) 231-2272 (499) 502-1214

ПАСПОРТ-СЕРТИФИКАТ ПРОИЗВОДИТЕЛЯ
на «Набор реагентов для определения групп крови человека систем АВО, Резус и Kell» по ТУ-9398-101-51203590-2009
(ЦОЛИКЛОНЫ Анти-А , Анти-В и Анти-АВ)

Наименование: Цоликлон Анти-В во флаконах по 10 мл с синими крышками

Серия: 282211 ОКП: 93 9816

Годен: 1 ноября 2020 г. Объем серии: 10000 мл.

Единица: 100 мл Паспорт: Т-18-11-92 от 27.11.2018

Количество единиц 50

Наименование показателя	Характеристика нормы	Результаты испытаний
1. Внешний вид 1.1 Цоликлон анти-А 1.2 Цоликлон анти-В 1.3 Цоликлон анти-АВ	Прозрачная жидкость красного цвета Прозрачная жидкость синего цвета Прозрачная бесцветная жидкость	Соответствует
2 Серологические свойства 2.1 Специфичность	Цоликлон анти-А не должен давать агглютинации с эритроцитами групп В(III) и О(I) Цоликлон анти-В не должен давать агглютинации с эритроцитами групп А(II) и О(I)	Соответствует Соответствует
2.2 Гемагглютинирующая способность	Цоликлон анти-АВ не должен давать агглютинации с эритроцитами группы О(I) Агглютинация на плоскости эритроцитов А1 и В с соответствующими Цоликлонами должна появиться не позднее 10 сек. после смешивания	Соответствует Соответствует 10 секунд
2.3 Титр	Титр Цоликлона анти-А в реакции агглютинации на плоскости с эритроцитами группы А(II) 1:32 - 1:64 Титр Цоликлона анти-В в реакции агглютинации на плоскости с эритроцитами группы В(III) 1:64 Титр Цоликлона анти-АВ в реакции агглютинации на плоскости с эритроцитами групп А(II) 1:32 - 1:64 и В(III) 1:64	Соответствует 1:32 - 1:64 Соответствует 1:64 Соответствует 1:32 - 1:64

Цоликлон соответствует требованиям ТУ 9398-101-51203590-2009

Заведующая лабораторией ООО «Медиклон»
М.С. Орлова

ООО "Медиклон"

МЕДИКЛОН
127276 Москва, Ботаническая ул. 35, т\ф (495) 231-2272 (499) 502-1214

ПАСПОРТ-СЕРТИФИКАТ ПРОИЗВОДИТЕЛЯ
на «Набор реагентов для определения групп крови человека систем АВО, Резус и Kell» по ТУ-9398-101-51203590-2009
(ЦОЛИКЛОНЫ Анти-А , Анти-В и Анти-АВ)

Наименование: Цоликлон Анти-А во флаконах по 10 мл с красными крышками

Серия: 282111 ОКП: 93 9816

Годен: 1 ноября 2020 г. Объем серии: 10000 мл.

Единица: 100 мл Паспорт: Т-18-11-91 от 22.11.2018

Количество единиц 50

Наименование показателя	Характеристика нормы	Результаты испытаний
1. Внешний вид 1.1 Цоликлон анти-А 1.2 Цоликлон анти-В 1.3 Цоликлон анти-АВ	Прозрачная жидкость красного цвета Прозрачная жидкость синего цвета Прозрачная бесцветная жидкость	Соответствует
2 Серологические свойства 2.1 Специфичность	Цоликлон анти-А не должен давать агглютинации с эритроцитами групп В(III) и О(I) Цоликлон анти-В не должен давать агглютинации с эритроцитами групп А(II) и О(I)	Соответствует Соответствует
2.2 Гемагглютинирующая способность	Цоликлон анти-АВ не должен давать агглютинации с эритроцитами группы О(I) Агглютинация на плоскости эритроцитов А1 и В с соответствующими Цоликлонами должна появиться не позднее 10 сек. после смешивания	Соответствует Соответствует 10 секунд
2.3 Титр	Титр Цоликлона анти-А в реакции агглютинации на плоскости с эритроцитами группы А(II) 1:32 - 1:64 Титр Цоликлона анти-В в реакции агглютинации на плоскости с эритроцитами группы В(III) 1:64 Титр Цоликлона анти-АВ в реакции агглютинации на плоскости с эритроцитами групп А(II) 1:32 - 1:64 и В(III) 1:64	Соответствует 1:32 - 1:64 Соответствует 1:64 Соответствует 1:32 - 1:64

Цоликлон соответствует требованиям ТУ 9398-101-51203590-2009

Заведующая лабораторией ООО «Медиклон»
М.С. Орлова

МЕДИКЛОН
127276 Москва, Ботаническая ул. 35 , т\ф (495) 231-2272 (499) 502-1214

ООО "Медиклон"

ПАСПОРТ-СЕРТИФИКАТ ПРОИЗВОДИТЕЛЯ

на «Набор реагентов для определения групп крови человека систем АВО, Резус и Kell» по ТУ-9398-101-51203590-2009

(ЦОЛИКЛОН Анти-Kell Супер)

Регистрационное удостоверение № ФСР 2009/06043 от 05 ноября 2009 г.

Наименование: Цоликлон Анти-Kell Супер

Серия: 181711 **ОКП:** 93 9816

Годен: 1 ноября 2020 г. **Объем серии:** 10000 мл.

Единица: 100 мл **Паспорт:** Т-18-11-91 от 22.11.2018

Количество единиц 10

Наименование показателя	Характеристика нормы по ТУ	Результаты испытаний
1.Внешний вид	Прозрачная желтоватая или розоватая жидкость	Соответствует
2. Серологические свойства		
2.1 Специфичность	Цоликлон Анти-Kell супер не должен агглютинировать эритроциты К(-)	Соответствует
2.2 Гемагглютинирующая способность	Четкая реакция агглютинации на плоскости должна наступить в течение 30 сек. после смешивания	Соответствует
2.2 Активность	Титр Цоликлона Анти-Kell Супер в пробирочной прямой агглютинации и микропланшете не ниже 1:16	Соответствует 1:16

Цоликлон соответствует требованиям ТУ 9398-101-51203590-2009

Заведующая лабораторией ООО «Медиклон»

М.С.Орлова

ФЕДЕРАЛЬНАЯ СЛУЖБА ПО НАДЗОРУ В СФЕРЕ ЗДРАВООХРАНЕНИЯ
(РОСЗДРАВНАДЗОР)

РЕГИСТРАЦИОННОЕ УДОСТОВЕРЕНИЕ НА МЕДИЦИНСКОЕ ИЗДЕЛИЕ

от 07 декабря 2015 года № ФСР 2011/11336

На медицинское изделие
Краситель - фиксатор эозин метиленовый синий по Май-Грюнвальду (МиниМед-М-Г) по ТУ 9398-004-29508133-2011

Настоящее регистрационное удостоверение выдано
**Общество с ограниченной ответственностью "МиниМед"
(ООО "МиниМед"), Россия,
241520, Брянская область, Брянский район, с. Супонево, ул. Шоссейная, д. 17А**

Производитель
**Общество с ограниченной ответственностью "МиниМед"
(ООО "МиниМед"), Россия,
241520, Брянская область, Брянский район, с. Супонево, ул. Шоссейная, д. 17А**

Место производства медицинского изделия
241520, Брянская область. Брянский район, с. Супонево, пер. Комсомольский, д. 7, корп. 2-а

Номер регистрационного досье **№ РД-9272/51850 от 18.11.2015**

Вид медицинского изделия **170510**

Класс потенциального риска применения медицинского изделия **3**

Код Общероссийского классификатора продукции для медицинского изделия **93 9816**

приказом Росздравнадзора от 07 декабря 2015 года № 9114
допущено к обращению на территории Российской Федерации.

**Руководитель Федеральной службы
по надзору в сфере здравоохранения** **М.А. Мурашко**

Declaration of Conformity

HL-7-0137DC DOI 2015/07 (7)

In Application of the Council Directive 98/79/EC on the approximation of the laws of the Member States relating to *In Vitro* Diagnostic Medical Devices & CE marking.

Declaration of conformance to applicable sections of Annex I - Essential Requirements and Annex III (EC Declaration of Conformity) imposed by sections 2 to 5. The below listed products are not classified under Annex II Lists A or B. Access to the appropriate technical files will be made available to the appropriate body in the event this is required.

Product Code	Description	GMDN Classification Code
5186	Routine Control N	30590

I, the undersigned declare that the devices registered against the above GMDN Classification Code conforms to the said Directives.

Full Name: M.J. Stephenson Title: Managing Director

Signed: Date: 28 Jul 2015

Tel +44 (0)191 482 8440
Fax +44 (0)191 482 8442
info@helena-biosciences.com
www.helena-biosciences.com

Helena Biosciences Europe
Queensway South, Team Valley Trading Estate,
Gateshead, Tyne and Wear, NE11 0SD.
United Kingdom

REFERENZWERTE

Referenzwerte können je nach Technik und verwendetem System von Labor zu Labor unterschiedlich sein. Aus diesem Grund sollte jedes Labor seine eigenen Referenzwertbereiche erstellen.

LEISTUNGSMERKMALE

Die folgenden Leistungseigenschaften wurden von Helena Biosciences Europe oder in ihrem Auftrag mit einem optomechanischen Gerinnungsgerät ermittelt. Jedes Labor muss seine eigenen Werte ermitteln.

Reproduzierbarkeit

		Intra-assay-Präzision	
Probe	*n*	*aPTT CV (%)*	*PT CV (%)*
Routine Control N	5	2.83	1.01
Routine Control A	5	2.76	1.71
Routine Control SA	5	1.72	1.03

LITERATURVERZEICHNIS

1. Kirkwood TBL *et al.* (1977) Identification of Sources of Variation in Factor VIII Assay. *British Journal of Haematology*, 37:559-568.
2. Goldenfarb MD (1971) Reproducibility in Coagulation Assays. *AJCP*, 55:561-564.
3. Palkuti HA and Longberry JR (1973) A Precision Study of Coagulation Factor Assay Techniques. *AJCP*, 59:231-235.

Plasmi di controllo della coagulazione
Istruzioni per l'uso

it

SCOPO PREVISTO

Il kit Coagulation Control Plasmas è concepito per l'uso come materiale di controllo qualità.

Routine Control N, Routine Control A e Routine Control SA sono destinati ad essere utilizzati come controlli normali, moderatamente prolungati e marcatamente prolungati per i dosaggi di PT e aPTT. Essi vengono dosati anche per fibrinogeno, TCT e ATIII e sono preparati con plasma umano normale.

AVVERTENZE E PRECAUZIONI

I reagenti contenuti in questo kit sono destinati esclusivamente alla diagnostica *in vitro*. NON INGERIRE. Indossare un'adeguata attrezzatura protettiva personale durante la manipolazione di tutti i componenti del kit. Per conoscere i relativi simboli precauzionali e di pericolo, laddove pertinente, fare riferimento alla dichiarazione di sicurezza del prodotto. Smaltire i componenti conformemente alle normative locali vigenti.

I prodotti ematici sono stati sottoposti a screening e trovati negativi (salvo diversa indicazione sulla confezione del kit o sulla fiala) per la presenza di:
Antigene dell'epatite B (HbsAg)
Anticorpo HIV 1
Anticorpo HIV 2
Anticorpo HCV
Questi prodotti devono tuttavia essere manipolati con le stesse misure precauzionali adottate per un campione paziente umano.

COMPOSIZIONE

REF	Componente	Contiene	Descrizione
5186	Routine Control - N	10 x 1 mL	Preparato con un pool di plasma normale
5187	Routine Control - A	10 x 1 mL	Preparati con plasma umano adsorbito
5183	Routine Control - SA	10 x 1 mL	Preparati con plasma umano adsorbito
5482	Routine Coagulation Control Set		
	Routine Control - N	4 x 1 mL	
	Routine Control - A	3 x 1 mL	
	Routine Control - SA	3 x 1 mL	

Ogni kit contiene un Istruzioni per l'uso.
Ogni kit contiene un inserto recante i valori di riferimento specifici per il lotto.

Ogni flacone contiene 1 mL di plasma umano tamponato liofilizzato.
Preparazione: Ricostituire ogni flacone di controllo appropriato con 1 mL di acqua distillata o deionizzata. Agitare delicatamente. Attendere 10 minuti per consentire al prodotto di sciogliersi completamente e miscelare bene prima dell'uso.

MATERIALI NECESSARI, MA NON IN DOTAZIONE

Il Coagulation Control Plasmas può essere utilizzato durante l'esecuzione di test su qualsiasi strumento di coagulazione meccanico o foto-ottico in combinazione con tutti i reagenti idonei disponibili in commercio.

CONSERVAZIONE, VITA UTILE E STABILITÀ

Ogni riferimento a nomi e dati utilizzati negli esempi è casuale, se non specificato diversamente. I controlli ricostituiti sono stabili per 8 ore se conservati a 2 – 8°C oppure 4 settimane a -20°C se congelati molto velocemente. Mantenere i prodotti coperti.

RACCOLTA E PREPARAZIONE DEI CAMPIONI

Non applicabile.

PROCEDURA

Ogni controllo deve essere trattato seguendo la stessa procedura adottata per il campione non noto, conformemente alle istruzioni riportate in ciascun protocollo di test specifico.

INTERPRETAZIONE DEI RISULTATI

Routine Control N deve fornire valori compresi nel range normale di laboratorio per i dosaggi di PT, aPTT e fibrinogeno. Routine Control A e Routine Control SA sono stati standardizzati per fornire, rispettivamente, tempi di PT e aPTT prolungati e marcatamente prolungati. I valori previsti specifici per il lotto e lo strumento vengono forniti con ciascuna confezione di controlli.

LIMITAZIONI

I risultati ottenuti con il Coagulation Control Plasmas dipendono da innumerevoli fattori, strettamente legati alla strumentazione, ai tipi di reagenti, ai substrati carenti e alle variazioni dovute ai singoli laboratori[1,2,3]. Ogni laboratorio dovrà definire un range di previsione per il sistema strumento-reagente specificamente utilizzato.

CONTROLLO QUALITÀ

Ogni laboratorio deve definire un programma di controllo qualità. I plasmi di controllo normali e anormali devono essere testati prima di ogni lotto di campioni di pazienti, per garantire un livello prestazionale soddisfacente sia per quanto riguarda lo strumento che per l'operatore. Qualora i controlli non funzionassero come previsto, i risultati relativi ai pazienti dovranno essere considerati non validi.

VALORI DI RIFERIMENTO

Per la sicurezza del paziente, è necessario che il sistema sia monitorato continuamente da un operatore qualificato. Per tale motivo ciascun laboratorio dovrà elaborare i propri range di riferimento.

CARATTERISTICHE PRESTAZIONALI

Le seguenti caratteristiche prestazionali sono state determinate da Helena Biosciences Europe o dai propri rappresentanti con l'utilizzo di uno strumento di coagulazione opto-meccanico. Ciascun laboratorio dovrà pertanto elaborare i propri dati prestazionali.

Riproducibilità

		Precisione intra-dosaggio	
Campione	*n*	*aPTT CV (%)*	*PT CV (%)*
Routine Control N	5	2.83	1.01
Routine Control A	5	2.76	1.71
Routine Control SA	5	1.72	1.03

BIBLIOGRAFIA

1. Kirkwood TBL *et al.* (1977) Identification of Sources of Variation in Factor VIII Assay. *British Journal of Haematology*, 37:559-568.
2. Goldenfarb MD (1971) Reproducibility in Coagulation Assays. *AJCP*, 55:561-564.
3. Palkuti HA and Longberry JR (1973) A Precision Study of Coagulation Factor Assay Techniques. *AJCP*, 59:231-235.

Plasmas de control de la coagulación
Instrucciones de uso

es

USO PREVISTO

El uso previsto del kit Coagulation Control Plasmas es como material de control de calidad.

Routine Control N, Routine Control A y Routine Control SA se usan como controles normal, moderadamente prolongado y notablemente prolongado para las valoraciones de TP y TTPa. También se valoran para fibrinógeno, TCT y ATIII y se elaboran a partir de plasma humano normal.

ADVERTENCIAS Y PRECAUCIONES

Los reactivos que contiene este kit son solo para uso de diagnóstico *in vitro*. NO INGERIR. Lleve el equipo de protección personal adecuado cuando utilice todos los componentes del kit. Consulte la declaración de seguridad del producto para saber más sobre las indicaciones adecuadas de advertencia y riesgo. Desechar los componentes de conformidad con las normativas locales.

La sangre se ha sometido a pruebas que han resultado negativas (a menos que se indique lo contrario en la caja del kit o en el vial) de la presencia de:
Antígeno de la hepatitis B (HbsAg)
Anticuerpos del VIH 1
Anticuerpos del VIH 2
Anticuerpos del VHC
Sin embargo, deben manipularse con las mismas precauciones que una muestra de un paciente.

COMPOSICIÓN

REF	Componente	Contiene	Descripción
5186	Routine Control - N	10 x 1 mL	Elabora a partir de plasma normal de reserva
5187	Routine Control - A	10 x 1 mL	Elaboran a partir de plasma humano adsorbido
5183	Routine Control - SA	10 x 1 mL	Elaboran a partir de plasma humano adsorbido
5482	Routine Coagulation Control Set		
	Routine Control - N	4 x 1 mL	
	Routine Control - A	3 x 1 mL	
	Routine Control - SA	3 x 1 mL	

Cada kit contiene instrucciones de uso.
Cada kit contiene valores de referencia específicos insertados del lote.

Cada vial contiene 1 mL de plasma humano tamponado, liofilizado.
Preparación: Reconstituya cada vial del control adecuado con 1 mL de agua destilada o desionizada. Agite suavemente. Deje que repose durante 10 minutos para que la disolución sea completa y mezcle bien antes de su uso.

ARTÍCULOS NECESARIOS NO SUMINISTRADOS

El Coagulation Control Plasmas puede usarse cuando se realizan pruebas con cualquier instrumento de coagulación mecánica o foto-óptica junto con todos los reactivos adecuados, comerciales.

ALMACENAMIENTO, CADUCIDAD Y ESTABILIDAD

Los viales no abiertos son estables hasta la fecha de caducidad indicada cuando se conservan en las condiciones indicadas en el vial o en la etiqueta del kit. Los controles reconstituidos son estables durante 8 horas cuando se conservan a 2 — 8°C o durante 4 semanas a -20°C cuando se conserva con congelación instantánea. Manténgase cubierto.

RECOGIDA Y PREPARACIÓN DE LAS MUESTRAS

No aplicable.

PROCEDIMIENTO

Cada control debe tratarse de la misma forma que la muestra desconocida, de acuerdo con las instrucciones indicadas en cada protocolo de prueba concreto.

INTERPRETACIÓN DE LOS RESULTADOS

Routine Control N debe dar valores dentro del intervalo normal de laboratorio para TP, TTPa y valoraciones de fibrinógeno. El Routine Control A y el Routine Control SA han sido estandarizados para dar tiempos de TP y TTPa prolongados y notablemente prolongados, respectivamente. Se aportan los valores esperados específicos de lote y de instrumento con cada paquete de controles.

LIMITACIONES

Los resultados obtenidos con Coagulation Control Plasmas dependen de varios factores fuertemente asociados a la instrumentación, los tipos de reactivos, sustratos deficientes y variaciones entre laboratorios[1,2,3]. Cada laboratorio debe establecer un intervalo esperado para el sistema instrumento-reactivo concreto.

CONTROL DE CALIDAD

Cada laboratorio debe establecer un programa de control de calidad. Los plasmas de control normales y anormales deben estudiarse antes de cada lote de muestras del paciente, para asegurar un funcionamiento adecuado del instrumento y el operador. Si los controles no se realizan como se esperaba, los resultados del paciente deben considerarse inválidos.

VALORES DE REFERENCIA

Los valores de referencia pueden variar entre los laboratorios dependiendo de las técnicas y sistemas usados. Por esta razón, cada laboratorio debe establecer sus propios intervalos de referencia.

CARACTERÍSTICAS FUNCIONALES

Las siguientes características de rendimiento han sido determinadas por Helena Biosciences Europe o sus representantes usando un instrumento de coagulación opto-mecánico. Cada laboratorio debe establecer sus propios datos de rendimiento.

Riproducibilità

		Precisión intra-ensayo	
Muestra	*n*	*TTPa CV (%)*	*TP CV (%)*
Routine Control N	5	2.83	1.01
Routine Control A	5	2.76	1.71
Routine Control SA	5	1.72	1.03

BIBLIOGRAFIA

1. Kirkwood TBL *et al.* (1977) Identification of Sources of Variation in Factor VIII Assay. *British Journal of Haematology*, 37:559-568.
2. Goldenfarb MD (1971) Reproducibility in Coagulation Assays. *AJCP*, 55:561-564.
3. Palkuti HA and Longberry JR (1973) A Precision Study of Coagulation Factor Assay Techniques. *AJCP*, 59:231-235.

КОНТРОЛЬНЫЕ ПЛАЗМЫ
инструкция

ru

НАЗНАЧЕНИЕ

[illegible]

[illegible]

ПРЕДУПРЕЖДЕНИЯ И МЕРЫ ПРЕДОСТОРОЖНОСТИ

[illegible]

[illegible]
Антиген к гепатиту B (HBsAg)
Антитела к ВИЧ 1
Антитела к ВИЧ 2
Антитела к вирусу гепатита C (HCV)
[illegible]

СОСТАВ

Кат. №	Компоненты	Состав набора	Описание
5186	Контроль качества, норма	10 x 1 мл	[illegible]
5187	Контроль качества, умеренно выраженная патология	10 x 1 мл	[illegible]
5183	Контроль качества, высокая патология	10 x 1 мл	[illegible]
5482	Контроль коагуляции, уровень 01		
	Контроль качества, норма	4 x 1 мл	
	Контроль качества, умеренно выраженная патология	3 x 1 мл	
	Контроль качества, высокая патология	3 x 1 мл	

Каждый набор содержит инструкцию по применению.
[illegible]

[illegible]
Подготовка: [illegible]

НЕОБХОДИМЫЕ КОМПОНЕНТЫ, НЕ ВКЛЮЧЕННЫЕ В КОМПЛЕКТ ПОСТАВКИ

[illegible]

ХРАНЕНИЕ, СРОК ГОДНОСТИ И УСТОЙЧИВОСТЬ

[illegible]

ОТБОР И ПОДГОТОВКА ОБРАЗЦОВ

Не относится.

ПРОЦЕДУРА

[illegible]

ИНТЕРПРЕТАЦИЯ РЕЗУЛЬТАТОВ

[illegible]

ОГРАНИЧЕНИЯ

[illegible]

КОНТРОЛЬ КАЧЕСТВА

[illegible]

НОРМАЛЬНЫЕ ПОКАЗАТЕЛИ

[illegible]

ЭКСПЛУАТАЦИОННЫЕ ХАРАКТЕРИСТИКИ

[illegible]

Воспроизводимость

		в пределах аналитической серии	
Контрольная плазма	Кол-во образцов	CV (%) АПТВ	CV (%) ПВ
Контроль качества, норма	5	2.83	1.01
Контроль качества, умеренно выраженная патология	5	2.76	1.71
Контроль качества, высокая патология	5	1.72	1.03

ЛИТЕРАТУРА

1. Kirkwood TBL, *et al.* (1977) Identification of Sources of Variation in Factor VIII Assay. *British Journal of Haematology*, 37:559-568.
2. Goldenfarb MD (1971) Reproducibility in Coagulation Assays. *AJCP*, 55:561-564.
3. Palkuti HA and Longberry JR (1973) A Precision Study of Coagulation Factor Assay Techniques. *AJCP*, 59:231-235.

Coagulation Control Plasmas

helena
Biosciences Europe

REF 5186 Routine Control N
REF 5187 Routine Control A
REF 5183 Routine Control SA
REF 5482 Routine Coagulation Control Set

CE IVD

Helena Biosciences Europe, Queensway South, Team Valley Trading Estate, Gateshead, Tyne and Wear, NE11 0SD, United Kingdom
Tel: +44 (0)191 482 8440
Fax: +44 (0)191 482 8442
Email: info@helena-biosciences.com
Web: www.helena-biosciences.com

HL-2-0482P 2016/01 (16)

Coagulation Control Plasmas
Instructions for use

en

INTENDED PURPOSE

The Coagulation Control Plasmas kit is intended for use as a quality control material.

Routine Control N, Routine Control A and Routine Control SA are for use as normal, moderately prolonged and markedly prolonged controls for PT and aPTT assays. They are also assayed for Fibrinogen, TCT and ATIII, and are prepared from normal human plasma.

WARNINGS AND PRECAUTIONS

The reagents contained in this kit are for *in vitro* diagnostic use only – DO NOT INGEST. Wear appropriate personal protective equipment when handling all kit components. Refer to the product safety declaration for the link to appropriate hazard and precautionary statements where applicable. Dispose of components in accordance with local regulations.

Blood products have been screened and found negative (unless otherwise stated on the kit box or vial) for the presence of:
Hepatitis B Antigen (HbsAg)
HIV 1 antibody HIV 2 antibody
HCV antibody
However they should be handled with the same precautions as a human patient sample.

COMPOSITION

REF	Component	Content	Description
5186	Routine Control - N	10 x 1 mL	Prepared from pooled normal plasma
5187	Routine Control - A	10 x 1 mL	Prepared from adsorbed human plasma
5183	Routine Control - SA	10 x 1 mL	Prepared from adsorbed human plasma
5482	Routine Coagulation Control Set		
	Routine Control - N	4 x 1 mL	
	Routine Control - A	3 x 1 mL	
	Routine Control - SA	3 x 1 mL	

Each kit contains instructions for use.
Each kit contains lot specific reference values insert.

Each vial contains 1 mL of buffered, lyophilised human plasma.
Preparation: Reconstitute each vial of the appropriate control with 1 mL of distilled or deionised water. Swirl gently. Allow to stand for 10 minutes for complete dissolution and mix well before use.

ITEMS REQUIRED BUT NOT PROVIDED

Coagulation Control Plasmas may be used when performing tests on any mechanical or photo-optical coagulation instrument in conjunction with all suitable, commercial reagents.

STORAGE, SHELF-LIFE AND STABILITY

Unopened vials are stable until the given expiry date when stored under conditions indicated on the vial or kit label. The reconstituted controls are stable for 8 hours when kept at 2 – 8°C or 4 weeks at -20°C when flash frozen. Keep covered.

SAMPLE COLLECTION AND PREPARATION

Not applicable.

PROCEDURE

Each control should be treated in the same manner as the unknown specimen in accordance with the instructions outlined in each particular test protocol.

INTERPRETATION OF RESULTS

Routine Control N should give values within the laboratory normal range for PT, aPTT and Fibrinogen assays. Routine Control A and Routine Control SA have been standardised to give prolonged and markedly prolonged PT and aPTT times respectively. Lot and instrument specific expected values are provided with each pack of controls.

LIMITATIONS

The results obtained with Coagulation Control Plasmas depend on several factors strongly associated with instrumentation, types of reagents, deficient substrates and laboratory to laboratory variations[1,2,3]. Each laboratory should establish an expected range for the particular instrument-reagent system.

QUALITY CONTROL

Each laboratory should establish a quality control program. Normal and abnormal control plasmas should be tested prior to each batch of patient samples, to ensure satisfactory instrument and operator performance. If controls do not perform as expected, patient results should be considered invalid.

REFERENCE VALUES

Reference values can vary between laboratories depending on the techniques and systems in use. For this reason each laboratory should establish its own reference ranges.

PERFORMANCE CHARACTERISTICS

The following performance characteristics have been determined by Helena Biosciences Europe or their representatives using an opto-mechanical coagulation instrument. Each laboratory should establish its own performance data.

Reproducibility

		Intra-assay precision	
Sample	*n*	*aPTT CV (%)*	*PT CV (%)*
Routine Control N	5	2.83	1.01
Routine Control A	5	2.76	1.71
Routine Control SA	5	1.72	1.03

BIBLIOGRAPHY

1. Kirkwood TBL, *et al.* (1977) Identification of Sources of Variation in Factor VIII Assay. *British Journal of Haematology*, 37:559-568.
2. Goldenfarb MD (1971) Reproducibility in Coagulation Assays. *AJCP*, 55:561-564.
3. Palkuti HA and Longberry JR (1973) A Precision Study of Coagulation Factor Assay Techniques. *AJCP*, 59:231-235.

Plasmas de contrôle de coagulation
Fiche technique

fr

UTILISATION

Le kit Coagulation Control Plasmas est destiné à être utilisé comme produit de contrôle qualité.

Les contrôles Routine Control N, Routine Control A et Routine Control SA servent de témoins normal, modérément prolongé et nettement prolongé dans les déterminations du TP et du TCA. Le fibrinogène, la TCT et l'ATIII ont été dosés et ils sont préparés à partir de plasma humain normal.

AVERTISSEMENTS ET PRÉCAUTIONS

Les réactifs du kit sont à usage diagnostique *in vitro* uniquement – NE PAS INGÉRER. Porter un équipement de protection individuelle approprié lors de la manipulation de tous les composants du kit. Consulter la fiche de données de sécurité du produit pour obtenir le lien vers les phrases de risque et les conseils de prudence le cas échéant. Éliminer les composants conformément aux réglementations locales.

Un dépistage des produits sanguins a été réalisé et a donné un résultat négatif (sauf indication contraire sur la boîte du kit ou sur le flacon) quant à la présence de :
Antigène de l'hépatite B (AgHBs)
Anticorps anti-VIH 1
Anticorps anti-VIH 2
Anticorps anti-VHC
Cependant, ils doivent être manipulés avec les mêmes précautions que celles prises pour les échantillons patients humains.

COMPOSITION

REF	Composant	Contient	Description
5186	Routine Control - N	10 x 1 mL	Préparé à partir d'un pool de plasma normal
5187	Routine Control - A	10 x 1 mL	Préparés à partir de plasma humain adsorbé
5183	Routine Control - SA	10 x 1 mL	Préparés à partir de plasma humain adsorbé
5482	Routine Coagulation Control Set		
	Routine Control - N	4 x 1 mL	
	Routine Control - A	3 x 1 mL	
	Routine Control - SA	3 x 1 mL	

Chaque kit contient une fiche technique.
Chaque kit contient valeurs de référence spécifiques du lot.

Chaque flacon contient 1 mL de plasma humain tamponné lyophilisé.
Préparation: Reconstituer chaque flacon du contrôle approprié avec 1 mL d'eau distillée ou désionisée. Agiter doucement. Attendre 10 minutes jusqu'à dissolution totale et bien mélanger avant d'utiliser.

MATÉRIEL NÉCESSAIRE NON FOURNI

Le Coagulation Control Plasmas peut être utilisé dans les analyses réalisées sur des instruments de coagulation mécanique ou photo-optique avec les réactifs appropriés vendus dans le commerce.

CONSERVATION, DURÉE DE VIE UTILE ET STABILITÉ

Les flacons non ouverts sont stables jusqu'à la date de péremption indiquée s'ils sont conservés dans les conditions indiquées sur l'étiquette du kit ou du flacon. Une fois reconstitués, les contrôles sont stables 8 heures entre 2 – 8°C ou 4 semaines à -20°C en cas de congélation instantanée. Couvrir le produit.

PRÉLÈVEMENT ET PRÉPARATION DES ÉCHANTILLONS

Non applicable.

PROCÉDURE

Chaque contrôle doit être traité de la même manière que l'échantillon à analyser en observant les instructions de chaque protocole spécifique.

INTERPRÉTATION DES RÉSULTATS

Le Routine Control N doit donner des valeurs se situant dans la plage normale du laboratoire pour le TP, le TCA et le fibrinogène. Le Routine Control A et le Routine Control SA ont été standardisés pour donner des temps TP et TCA prolongés et très prolongés respectivement. Les valeurs prévues spécifiques du lot et de l'instrument sont fournies avec chaque kit de contrôles.

LIMITES

Les résultats obtenus avec le Coagulation Control Plasmas dépendent de plusieurs facteurs fortement corrélés avec l'instrument, les types de réactifs, les substrats carencés et les variations inter-laboratoires[1,2,3]. Le laboratoire doit déterminer une plage attendue pour chaque système instrument-réactif.

CONTRÔLE QUALITÉ

Chaque laboratoire doit établir un programme de contrôle qualité. Les plasmas de contrôle normaux et anormaux doivent être testés avant chaque lot d'échantillons patients afin de s'assurer que l'instrument et l'opérateur offrent des performances satisfaisantes. Si les contrôles ne donnent pas les résultats prévus, les résultats du patient doivent être considérés comme non valables.

VALEURS DE RÉFÉRENCE

Les valeurs de référence peuvent varier d'un laboratoire à l'autre suivant les techniques et les systèmes utilisés. C'est pour cette raison qu'il appartient à chaque laboratoire de déterminer ses propres plages de référence.

CARACTÉRISTIQUES DE PERFORMANCES

Helena Biosciences Europe ou ses mandataires ont déterminé les caractéristiques de performance suivantes en utilisant un instrument de coagulation opto-mécanique. Chaque laboratoire doit établir ses propres données de performance.

Reproductibilité

		Précision intra-série	
Échantillon	*n*	*TCA CV (%)*	*TP CV (%)*
Routine Control N	5	2.83	1.01
Routine Control A	5	2.76	1.71
Routine Control SA	5	1.72	1.03

BIBLIOGRAPHIE

1. Kirkwood TBL, *et al.* (1977) Identification of Sources of Variation in Factor VIII Assay. *British Journal of Haematology*, 37:559-568.
2. Goldenfarb MD (1971) Reproducibility in Coagulation Assays. *AJCP*, 55:561-564.
3. Palkuti HA and Longberry JR (1973) A Precision Study of Coagulation Factor Assay Techniques. *AJCP*, 59:231-235.

Kontrollplasma für die Gerinnung
Anleitung

de

VERWENDUNGSZWECK

Das Coagulation Control Plasmas-Kit ist für die Qualitätskontrolle vorgesehen.

Routine Control N, Routine Control A und Routine Control SA sind als normale, mäßig verlängerte und stark verlängerte Kontrollen für PT und aPTT Tests geeignet. Sie sind auch auf Fibrinogen, TZ und AT-III getestet und werden aus normalem Humanplasma hergestellt.

WARNHINWEISE UND VORSICHTSMASSNAHMEN

Die in diesem Kit enthaltenen Reagenzien sind ausschließlich für die Verwendung von *in-vitro*-Diagnosen vorgesehen. NICHT VERSCHLUCKEN. Tragen Sie beim Umgang mit sämtlichen Komponenten des Kits geeignete Schutzausrüstung. Beachten Sie gegebenenfalls die Verweise auf entsprechende Gefahren- und Vorsorgeerklärungen in der Produktsicherheitserklärung. Entsorgen Sie die Komponenten gemäß den örtlichen Vorschriften.

Die Blutprodukte wurden untersucht und sind für folgende Gene ohne Befund (sofern nicht anderweitig auf der Verpackung oder dem Ampullen angegeben):
Hepatitis-B-Antikörper (HBsAg)
HIV-Antikörper 1
HIV-Antikörper 2
HCV-Antikörper
Sie sind jedoch mit den gleichen Vorkehrungen zu behandeln wie Proben von menschlichen Patienten.

ZUSAMMENSETZUNG

REF	Komponente	Inhalt	Beschreibung
5186	Routine Control - N	10 x 1 mL	Aus gepooltem Humanplasma hergestellt
5187	Routine Control - A	10 x 1 mL	Adsorbiertem Humanplasma hergestellt
5183	Routine Control - SA	10 x 1 mL	Adsorbiertem Humanplasma hergestellt
5482	Routine Coagulation Control Set		
	Routine Control - N	4 x 1 mL	
	Routine Control - A	3 x 1 mL	
	Routine Control - SA	3 x 1 mL	

Jedes Kit enthält eine Gebrauchsanweisung.
Jedes Kit enthält chargenspezifischen Referenzwerten.

Jedes Fläschchen enthält 1 mL gepuffertes, lyophilisiertes Humanplasma.
Vorbereitung: Jedes Fläschchen Kontrollplasma mit 1 mL destilliertem oder entionisiertem Wasser rekonstituieren. Leicht schwenken. Zum vollständigen Auflösen 10 Minuten stehen lassen und vor Gebrauch gut mischen.

ERFORDERLICHE, ABER NICHT MITGELIEFERTE ARTIKEL

Coagulation Control Plasmas kann in Verbindung mit allen entsprechenden kommerziellen Reagenzien bei der Durchführung von Tests an mechanischen oder fotooptischen Koagulometern verwendet werden.

LAGERUNG, HALTBARKEIT UND STABILITÄT

Ungeöffnete Fläschchen sind unter den auf Verpackung oder Fläschchen angegebenen Aufbewahrungsbedingungen bis zum aufgedruckten Verfallsdatum stabil. Rekonstituierte Kontrollen sind bei 2 – 8°C 8 Stunden stabil bzw. 4 Wochen bei -20°C, wenn schockgefroren. Verschlossen aufbewahren.

PROBENENTNAHME UND VORBEREITUNG

Entfällt.

VORGEHENSWEISE

Jede Kontrolle sollte gemäß den Anleitungen der einzelnen Testprotokolle wie unbekannte Probe behandelt werden.

INTERPRETATION DER ERGEBNISSE

Routine Control N sollte für PT, aPTT und Fibrinogen Tests Werte im Normalbereich ergeben. Routine Control A und Routine Control SA wurden standardisiert, um verlängerte bzw. stark verlängerte PT und aPTT Zeiten zu ergeben. Chargen- und Geräte-spezifische Normalwerte sind in jeder Packung mit Kontrollen enthalten.

EINSCHRÄNKUNGEN

Die mit Coagulation Control Plasmas erzielten Resultate hängen von mehreren Faktoren ab, die stark mit dem Gerät, den verwendeten Reagenzien, mangelnden Substraten und Unterschieden zwischen den Labors in Verbindung stehen[1,2,3]. Jedes Labor sollte daher für jedes Geräte/Reagenzien-System einen eigenen Erwartungsbereich ermitteln.

QUALITÄTSKONTROLLE

Jedes Labor muss für eine eigene Qualitätskontrolle sorgen. Normale und pathologische Kontrollplasmen sollten vor jeder Testreihe mit Patientenproben getestet werden, um eine zufriedenstellende Geräte- und Bedienerleistung zu gewährleisten. Liegen die Kontrollen außerhalb des Normbereichs, sind die Patientenergebnisse nicht zu verwenden.

SOCIETATEA … S.R.L. … REPUBLICA MOLDOVA

Declaration of Conformity

HL-7-0135DC DOI 2015/07 (7)

In Application of the Council Directive 98/79/EC on the approximation of the laws of the Member States relating to *In Vitro* Diagnostic Medical Devices & CE marking.

Declaration of conformance to applicable sections of Annex I - Essential Requirements and Annex III (EC Declaration of Conformity) imposed by sections 2 to 5. The below listed products are not classified under Annex II Lists A or B. Access to the appropriate technical files will be made available to the appropriate body in the event this is required.

Product Code	Description	GMDN Classification Code
5183	Routine Control SA	30590

I, the undersigned declare that the devices registered against the above GMDN Classification Code conforms to the said Directives.

Full Name: M.J. Stephenson

Title: Managing Director

Signed:

Date: 28 Jul 2015

Tel +44 (0)191 482 8440
Fax +44 (0)191 482 8442
info@helena-biosciences.com
www.helena-biosciences.com

Helena Biosciences Europe
Queensway South, Team Valley Trading Estate,
Gateshead, Tyne and Wear. NE11 0SD.
United Kingdom

Declaration of Conformity

HL-7-0138DC DOI 2015/07 (7)

In Application of the Council Directive 98/79/EC on the approximation of the laws of the Member States relating to *In Vitro* Diagnostic Medical Devices & CE marking.

Declaration of conformance to applicable sections of Annex I - Essential Requirements and Annex III (EC Declaration of Conformity) imposed by sections 2 to 5. The below listed products are not classified under Annex II Lists A or B. Access to the appropriate technical files will be made available to the appropriate body in the event this is required.

Product Code	Description	GMDN Classification Code
5187	Routine Control A	30590

I, the undersigned declare that the devices registered against the above GMDN Classification Code conforms to the said Directives.

Full Name: M.J. Stephenson

Title: Managing Director

Signed:

Date: 28 Jul 2015

Tel +44 (0)191 482 8440
Fax +44 (0)191 482 8442
info@helena-biosciences.com
www.helena-biosciences.com

Helena Biosciences Europe
Queensway South, Team Valley Trading Estate,
Gateshead, Tyne and Wear. NE11 0SD.
United Kingdom

TÜVRheinland®

EC Certificate

Directive 98/79/EC Annex IV, excluding Sections 4 and 6
Full Quality Assurance System
In Vitro Diagnostic Medical Devices

Registration No.: HL 60119814 0001

Report No.: 21265422 001

Manufacturer:
Macherey-Nagel GmbH & Co. KG
Neumann-Neander-Str. 6-8
52355 Düren
Deutschland

Products:
Products for self-testing

(see attachment for products and sites included)

Replaces Certificate, Registration No.: HL 60076687 0001

Expiry Date: 2022-05-28

The Notified Body hereby declares that the requirements of Annex IV, excluding section 4 and 6 of the directive 98/79/EC have been met for the listed products. The above named manufacturer has established and applies a quality assurance system, which is subject to periodic surveillance, defined by Annex IV, section 5 of the aforementioned directive. For placing on the market of List A devices covered by this certificate an EC design-examination certificate according to Annex IV, section 4 and a verification of manufactured products according to section 6 is required.

Notified Body

Effective Date: 2017-05-29

Date: 2017-05-29

Dipl.-Ing. Sven Hoffmann

TÜV Rheinland LGA Products GmbH - Tillystraße 2 - 90431 Nürnberg

TÜV Rheinland LGA Products GmbH is a Notified Body according to Directive 98/79/EC concerning in vitro diagnostic medical devices with the identification number 0197.

TÜVRheinland®

Doc. 1/1, Rev. 0

TÜV Rheinland
LGA Products GmbH
Tillystraße 2, 90431 Nürnberg

Attachment to
Certificate
Registration No.: HL 60119814 0001
Report No.: 21265422 001

Manufacturer: Macherey-Nagel GmbH & Co. KG
Neumann-Neander-Str. 6-8
52355 Düren
Deutschland

Products for self-testing:
- Single and multi-parameter disposable test strips for urine analysis
- indicator test strips and papers for measurement of pH in urine

Additional site for warehousing and logistics:

Bahnstr. 120
52355 Düren, Germany

Notified Body

Date: 2017-05-29

Dipl.-Ing. Sven Hoffmann

Il presente documento annulla e sostituisce il certificato di pari numero emesso in data 24/04/2018.

CISQ is a member of

IQNet
THE INTERNATIONAL CERTIFICATION NETWORK
www.iqnet-certification.com

IQNet, the association of the world's first class certification bodies, is the largest provider of management System Certification in the world. IQNet is composed of more than 30 bodies and counts over 150 subsidiaries all over the globe.

ICIM

CERTIFICATO n. / *CERTIFICATE No.* **4265/3**

SI CERTIFICA CHE IL SISTEMA DI GESTIONE PER LA QUALITÀ DI
WE HEREBY CERTIFY THAT THE QUALITY MANAGEMENT SYSTEM OPERATED BY

GRUPPO VACUTEST KIMA

Sede / *Head Office*
Via dell'Industria,12 – 35020 Arzergrande (PD)
Unità Operative / *Operative Units*
MEUS S.r.l. - Via Leonardo da Vinci, 24B – 26 – 28 – Zona Industriale Tognana – 35028 Piove di Sacco (PD)
MEUS S.r.l. - Via dell'Industria, 2 - 16 – 35020 Arzergrande (PD)
ROLL S.a.s. - Via Leonardo Da Vinci, 24A – Zona Industriale Tognana – 35028 Piove di Sacco (PD)
KIMA S.a.s. - Via Leonardo da Vinci, 22 – Zona Industriale Tognana – 35028 Piove di Sacco (PD)
VACUTEST KIMA S.r.l. - Via dell'Industria,12 – 35020 Arzergrande (PD)
Italia

È CONFORME ALLA NORMA / *IS IN COMPLIANCE WITH THE STANDARD*

UNI CEI EN ISO 13485:2016

Sistema di Gestione per la Qualità / *Quality Management System*

PER LE SEGUENTI ATTIVITÀ / *FOR THE FOLLOWING ACTIVITIES*

EA: 14 - 29

Progettazione e produzione di provette con vuoto predeterminato ad uso prelievo ematico, liquidi biologici e urine. Produzione di provette per microprelievi di sangue. Produzione di Holders (camicie) per prelievo sottovuoto. Progettazione e produzione di kit diagnostici per l'analisi del sangue e dei liquidi biologici. Progettazione e produzione di terreni di coltura per microbiologia. Progettazione e produzione di aghi e dispositivi sterili per il prelievo ematico. Commercializzazione di prodotti del Gruppo: kit diagnostici, terreni di coltura per microbiologia, articoli in plastica per laboratorio analisi, provette con vuoto predeterminato e aghi sterili. Progettazione e produzione di stampi per articoli in plastica per laboratorio analisi. Stampaggio di materie termoplastiche ad iniezione per articoli medicali.

Design and production of test tubes with predetermined vacuum for collection of haematological samples, biological liquids and urine samples. Production of test tubes for micro-collection of haematological samples. Production of Holders for vacuum sampling. Design and production of diagnostic kits for blood and biological liquids analysis. Design and production of culture media for microbiology. Design and production of sterile needles and devices for collection of haematological samples. Trading of the products of the Group: diagnostic kits, culture media for microbiology, plastic disposable labware, test tubes with predetermined vacuum and sterile needles. Design and production of moulds for plastic labware. Injection moulding of thermoplastic materials for medical devices.

Riferirsi alla documentazione del Sistema di Gestione per la Qualità aziendale per l'applicabilità dei requisiti della norma di riferimento.
Refer to the documentation of the Quality Management System for details of application to reference standard requirements.

Per informazioni puntuali e aggiornate circa eventuali variazioni intervenute nello stato della certificazione di cui al presente certificato, si prega di contattare il n° telefonico +39 02 725341 o indirizzo e-mail info@icim.it.
For timely and updated information about any changes in the certification status referred to in this certificate, please contact the number +39 02 725341 or email address info@icim.it.

Data emissione	Emissione corrente	Data di scadenza
First issue	*Current issue*	*Expiring date*
18/01/2007	15/06/2018	17/01/2019

ICIM S.p.A.
Piazza Don Enrico Mapelli, 75 – 20099 Sesto San Giovanni (MI)
www.icim.it

ACCREDIA
L'ENTE ITALIANO DI ACCREDITAMENTO

SGQ	N° 004 A	PRD	N° 004 B
SGA	N° 005 D	PRS	N° 082 C
SGE	N° 005 M	ISP	N° 046 E
SCR	N° 006 F	ETS	N° 003 O
SSI	N° 008 G	EMAS	N° 001 P

Membro degli Accordi di Mutuo Riconoscimento EA, IAF e ILAC
Signatory of EA, IAF and ILAC Mutual Recognition Agreements

FEDERAZIONE CISQ
www.cisq.com
CISQ è la Federazione Italiana di Organismi di Certificazione dei sistemi di gestione aziendale.
CISQ is the Italian Federation of management system Certification Bodies.

Il presente documento annulla e sostituisce il certificato di pari numero emesso in data 24/04/2018.

CISQ is a member of

IQNet
THE INTERNATIONAL CERTIFICATION NETWORK
www.iqnet-certification.com

IQNet, the association of the world's first class certification bodies, is the largest provider of management System Certification in the world. IQNet is composed of more than 30 bodies and counts over 150 subsidiaries all over the globe.

ICIM

CERTIFICATO n. / *CERTIFICATE No.* **4264/3**

SI CERTIFICA CHE IL SISTEMA DI GESTIONE PER LA QUALITÀ DI
WE HEREBY CERTIFY THAT THE QUALITY MANAGEMENT SYSTEM OPERATED BY

GRUPPO VACUTEST KIMA

Sede / *Head Office*
Via dell'Industria,12 – 35020 Arzergrande (PD)
Unità Operative / *Operative Units*
MEUS S.r.l. - Via Leonardo da Vinci, 24B – 26 – 28 – Zona Industriale Tognana – 35028 Piove di Sacco (PD)
MEUS S.r.l. - Via dell'Industria, 2 - 16 – 35020 Arzergrande (PD)
ROLL S.a.s. - Via Leonardo Da Vinci, 24A – Zona Industriale Tognana – 35028 Piove di Sacco (PD)
KIMA S.a.s. - Via Leonardo da Vinci, 22 – Zona Industriale Tognana – 35028 Piove di Sacco (PD)
VACUTEST KIMA S.r.l. - Via dell'Industria,12 – 35020 Arzergrande (PD)
Italia

È CONFORME ALLA NORMA / *IS IN COMPLIANCE WITH THE STANDARD*

UNI EN ISO 9001:2015

Sistema di Gestione per la Qualità / *Quality Management System*

PER LE SEGUENTI ATTIVITÀ / *FOR THE FOLLOWING ACTIVITIES*

EA: 14 - 29

Progettazione e produzione di provette con vuoto predeterminato ad uso prelievo ematico, liquidi biologici e urine. Produzione di provette per microprelievi di sangue. Produzione di Holders (camicie) per prelievo sottovuoto. Progettazione e produzione di kit diagnostici per l'analisi del sangue e dei liquidi biologici. Progettazione e produzione di terreni di coltura per microbiologia. Progettazione e produzione di aghi e dispositivi sterili per il prelievo ematico. Commercializzazione di prodotti del Gruppo: kit diagnostici, terreni di coltura per microbiologia, articoli in plastica per laboratorio analisi, provette con vuoto predeterminato e aghi sterili. Progettazione e produzione di stampi per articoli in plastica per laboratorio analisi. Stampaggio di materie termoplastiche ad iniezione per articoli medicali.

Design and production of test tubes with predetermined vacuum for collection of haematological samples, biological liquids and urine samples. Production of test tubes for micro-collection of haematological samples. Production of Holders for vacuum sampling. Design and production of diagnostic kits for blood and biological liquids analysis. Design and production of culture media for microbiology. Design and production of sterile needles and devices for collection of haematological samples. Trading of the products of the Group: diagnostic kits, culture media for microbiology, plastic disposable labware, test tubes with predetermined vacuum and sterile needles. Design and production of moulds for plastic labware. Injection moulding of thermoplastic materials for medical devices.

Riferirsi alla documentazione del Sistema di Gestione per la Qualità aziendale per l'applicabilità dei requisiti della norma di riferimento.
Refer to the documentation of the Quality Management System for details of application to reference standard requirements.

Il presente certificato è soggetto al rispetto del documento ICIM "Regolamento per la certificazione dei sistemi di gestione" e al relativo Schema specifico.
The use and the validity of this certificate shall satisfy the requirements of the ICIM document "Rules for the certification of company management systems" and specific Scheme.

Per informazioni puntuali e aggiornate circa eventuali variazioni intervenute nello stato della certificazione di cui al presente certificato, si prega di contattare il n° telefonico +39 02 725341 o indirizzo e-mail info@icim.it.
For timely and updated information about any changes in the certification status referred to in this certificate, please contact the number +39 02 725341 or email address info@icim.it..

Data emissione	Emissione corrente	Data di scadenza
First issue	*Current issue*	*Expiring date*
18/01/2007	15/06/2018	17/01/2019

ICIM S.p.A.
Piazza Don Enrico Mapelli, 75 – 20099 Sesto San Giovanni (MI)
www.icim.it

ACCREDIA
L'ENTE ITALIANO DI ACCREDITAMENTO

SGQ	N° 004 A	PRD	N° 004 B
SGA	N° 005 D	PRS	N° 082 C
SGE	N° 005 M	ISP	N° 046 E
SCR	N° 006 F	ETS	N° 003 O
SSI	N° 008 G	EMAS	N° 001 P

Membro degli Accordi di Mutuo Riconoscimento EA, IAF e ILAC
Signatory of EA, IAF and ILAC Mutual Recognition Agreements

FEDERAZIONE CISQ
www.cisq.com
CISQ è la Federazione Italiana di Organismi di Certificazione dei sistemi di gestione aziendale.
CISQ is the Italian Federation of management system Certification Bodies.

ITALCERT

CERTIFICATO N° 505DM05

CERTIFICATE N° 505DM05

Si certifica che il
this is to certify that

Sistema di Gestione per la Qualità

Quality Management System

messo in atto da
implemented by

NUOVA APTACA S.r.l.

Via Monte Bianco, 4 – IT 20900 MONZA (MB)

nella Sede Operativa di
Operative Unit

Regione Monforte, 30 – IT 14053 CANELLI (AT)

è conforme alla norma
is in compliance with the standard

UNI CEI EN ISO 13485-2016 (ISO 13485-2016)

per i seguenti Processi
concerning the following kinds of Processes

Gestione della fabbricazione e immissione in commercio di tamponi sterili per il prelievo di campioni biologici in orifizi naturali e in ambito chirurgico. Progettazione e fabbricazione di dispositivi medico diagnostici per laboratori di analisi. Commercializzazione di dispositivi medici e diagnostici in vitro.

Management of manufacturing and placing on the market of sterile tampons for sampling of biological specimens in natural orifice and in surgical field. Design and manufacturing of diagnostic medical devices for analysis laboratories. Marketing of medical and diagnostic devices in vitro.

Il presente Certificato è soggetto al rispetto delle condizioni stabilite dai Regolamenti per la certificazione in vigore applicabili.
This Certificate shall satisfy the requirements established in the Rules for the certification in force applicable.
In caso di discordanza tra le lingue utilizzate nella traduzione del contenuto del presente certificato, fare riferimento alla lingua italiana
In cases of discrepancy between the languages used in the translation of the content of this certificate, please refer to the Italian language

L'AMMINISTRATORE DELEGATO
MANAGING DIRECTOR

Dr. Ing. Roberto Cusolito

Data di Prima Emissione *First Issue Date*	Data di Prima Emissione ITALCERT *First Issue Date ITALCERT*	Data di Rinnovo *Renewal Date*	Data di Delibera *Deliberation Date*	Data di Scadenza *Expiration Date*
2007-10-30	2011-10-30	2017-10-30	2019-01-04	2020-10-29

ACCREDIA
L'ENTE ITALIANO DI ACCREDITAMENTO
SGQ N° 023A
Membro degli Accordi di Mutuo Riconoscimento EA, IAF e ILAC
Signatory of EA, IAF and ILAC Mutual Recognition Agreements

ITALCERT S.r.l. | Viale Sarca, 336 – 20126 Milano (MI) | tel. +39 0266104876 | fax. +39 0266101479 | www.italcert.it | italcertsrl@legalmail.it

ITALCERT

CERTIFICATO N° 505SGQ03

CERTIFICATE N° 505SGQ03

Si certifica che il
this is to certify that

Sistema di Gestione per la Qualità

Quality Management System

messo in atto da
implemented by

NUOVA APTACA S.r.l.

Via Monte Bianco, 4 – IT 20900 MONZA (MB)

nella Sede Operativa di
Operative Unit

Regione Monforte, 30 – IT 14053 CANELLI (AT)

è conforme alla norma
is in compliance with the standard

UNI EN ISO 9001-2015 (ISO 9001-2015)

per i seguenti Processi
concerning the following kinds of Processes

Gestione della fabbricazione ed immissione in commercio di tamponi sterili per il prelievo di campioni biologici in orifizi naturali e in ambito chirurgico.
Progettazione e fabbricazione di dispositivi medico diagnostici per laboratori di analisi.
Commercializzazione di dispositivi medici e diagnostici in vitro.
Commercializzazione di articoli da laboratorio

Management of the manufacturing and placing on the market of sterile tampons for sampling of biological specimens in natural orifice and in surgical field. Design and manufacturing of diagnostic medical devices for laboratories of analysis. Marketing of medical and diagnostic devices in vitro. Marketing of laboratory articles

Il presente Certificato è soggetto al rispetto delle condizioni stabilite dai Regolamenti per la certificazione in vigore applicabili.
This Certificate shall satisfy the requirements established in the Rules for the certification in force applicable.
In caso di discordanza tra le lingue utilizzate nella traduzione del contenuto del presente certificato, fare riferimento alla lingua italiana
In cases of discrepancy between the languages used in the translation of the content of this certificate, please refer to the italian language

L'AMMINISTRATORE DELEGATO
MANAGING DIRECTOR

Dr. Ing. Roberto Cusolito

Data di Prima Emissione *First Issue Date*	Data di Prima Emissione ITALCERT *First Issue Date ITALCERT*	Data di Rinnovo *Renewal Date*	Data di Scadenza *Expiration Date*
1998-07-23	2011-10-30	2017-10-30	2020-10-29

Settore IAF 14 - 29

ACCREDIA
L'ENTE ITALIANO DI ACCREDITAMENTO
SGQ N° 023A PRD N° 122B
SGA N° 020D ISP N° 075E
PRS N° 037C
Membro degli Accordi di Mutuo Riconoscimento EA, IAF e ILAC
Signatory of EA, IAF and ILAC Mutual Recognition Agreements

SOCIETATEA CU RĂSPUNDERE LIMITATĂ "GBG-MLD" Nr.4 IDNO 1003600117562 MOLDOVA, MUN.

Certificado ES10/81672

The management system of

DELTALAB, S.L.

Pol. Ind. La Llana, Plaza De La Verneda, 1
08191 Rubí (Barcelona)

has been assessed and certified as meeting the requirements of

ISO 9001:2015

For the following activities

Design, manufacture and sale of laboratory material for the collection, transport and conservation of samples for microbiological, molecular biology, haematology, biochemistry, histology, microscopy and colorimetric analysis. Commercialization of equipment for the storage of prepared samples, cryogenic stored samples, general labware and industrial packages.

Diseño, fabricación y comercialización de material de laboratorio para la toma, transporte y conservación de muestras para análisis de microbiología, biología molecular, hematología, bioquímica, histología, microscopía y coloración. Comercialización de equipos para el almacenamiento de muestras preparadas, almacenamiento de muestras para criogenización, material general de laboratorio y envases industriales.

in/ from the following sites

Pol. Ind. La Llana, Plaza De La Verneda 1 - 08191 Rubí (Barcelona)

This certificate is valid from
29 November 2017 until 11 October 2019.
Issue 7. Certified since October 2010.

Este certificado es válido desde
29 de noviembre de 2017 hasta 11 de octubre de 2019.
Edición 7. Certificado desde octubre de 2010..

Authorized by

Dirección de Certificación

SGS ICS Ibérica, S.A. (Unipersonal)
C/Trespaderne, 29. 28042 Madrid. España.
t 34 91 313 8115 f 34 91 313 8102 www.sgs.com

LORNE LABORATORIES

EC DECLARATION OF CONFORMITY

Lorne Laboratories Ltd declares that the following in vitro diagnostic reagent:

Product name	Catalogue number
CRP Latex kit	850100A

has been classified as non List A, non List B (Directive 98/79/EC, Annex II) and complies with the essential requirements and provisions of Directive 98/79/EC of the European Parliament and of the Council (also SI 2002 No.618 which transposes the requirements of Directive 98/79/EC).

and is in conformity with the national standards transposing harmonised standards:

- BS EN 980:2008
- BS EN ISO 13485:2012
- BS EN 13612:2002
- BS EN 13640:2002
- BS EN 13641:2002
- BS EN ISO 14971:2012
- BS EN ISO 18113, parts 1&2

The conformity assessment procedure performed was in accordance with Annex III of Directive 98/79/EC.

This declaration of conformity is issued under the sole responsibility of Lorne Laboratories Ltd and is valid from 13 April 2016.

Eddy Velthuis
Technical Director

Lorne Laboratories Limited
Unit 1 Cutbush Park Industrial Estate
Danehill, Lower Earley
Berkshire RG6 4UT United Kingdom

Tel: +44 (0) 118 921 2264
Fax: +44 (0) 118 986 4518
Email: info@lornelabs.com
www.lornelabs.com

LORNE LABORATORIES

EC DECLARATION OF CONFORMITY

Lorne Laboratories Ltd declares that the following in vitro diagnostic reagent:

Product name	Catalogue number
ASO Latex kit	031100A

has been classified as non List A, non List B (Directive 98/79/EC, Annex II) and complies with the essential requirements and provisions of Directive 98/79/EC of the European Parliament and of the Council (also SI 2002 No.618 which transposes the requirements of Directive 98/79/EC).

and is in conformity with the national standards transposing harmonised standards:

- BS EN 980:2008
- BS EN ISO 13485:2012
- BS EN 13612:2002
- BS EN 13640:2002
- BS EN 13641:2002
- BS EN ISO 14971:2012
- BS EN ISO 18113, parts 1&2

The conformity assessment procedure performed was in accordance with Annex III of Directive 98/79/EC.

This declaration of conformity is issued under the sole responsibility of Lorne Laboratories Ltd and is valid from 13 April 2016.

Eddy Velthuis
Technical Director

Lorne Laboratories Limited
Unit 1 Cutbush Park Industrial Estate
Danehill, Lower Earley
Berkshire RG6 4UT United Kingdom

Tel: +44 (0) 118 921 2264
Fax: +44 (0) 118 986 4518
Email: info@lornelabs.com
www.lornelabs.com

LORNE LABORATORIES

EC DECLARATION OF CONFORMITY

Lorne Laboratories Ltd declares that the following in vitro diagnostic reagent:

Product name	Catalogue number
RF Latex kit	830100A

has been classified as non List A, non List B (Directive 98/79/EC, Annex II) and complies with the essential requirements and provisions of Directive 98/79/EC of the European Parliament and of the Council (also SI 2002 No.618 which transposes the requirements of Directive 98/79/EC).

and is in conformity with the national standards transposing harmonised standards:

- BS EN 980:2008
- BS EN ISO 13485:2012
- BS EN 13612:2002
- BS EN 13640:2002
- BS EN 13641:2002
- BS EN ISO 14971:2012
- BS EN ISO 18113, parts 1&2

The conformity assessment procedure performed was in accordance with Annex III of Directive 98/79/EC.

This declaration of conformity is issued under the sole responsibility of Lorne Laboratories Ltd and is valid from 13 April 2016.

Eddy Velthuis
Technical Director

Lorne Laboratories Limited
Unit 1 Cutbush Park Industrial Estate
Danehill, Lower Earley
Berkshire RG6 4UT United Kingdom

Tel: +44 (0) 118 921 2264
Fax: +44 (0) 118 986 4518
Email: info@lornelabs.com
www.lornelabs.com

TÜVRheinland®

Certificate

The Certification Body of
TÜV Rheinland LGA Products GmbH

hereby certifies that the organization

KABE LABORTECHNIK GmbH
Jägerhofstr. 17
51588 Nümbrecht
Deutschland

has established and applies a quality management system for medical devices for the following scope:

Design and development, production and distribution of in vitro diagnostic products and consumption materials for sample withdrawal, preparation and storage as well as single-use medical devices

Proof has been furnished that the requirements specified in

EN ISO 13485:2012
EN ISO 13485:2012/AC:2012

are fulfilled. The quality management system is subject to yearly surveillance.

Effective Date:	2015-10-16
Certificate Registration No.:	SX 60105391 0001
An audit was performed. Report No.:	21234760 001
This Certificate is valid until:	2018-10-15

Certification Body

DAkkS
Deutsche Akkreditierungsstelle
D-ZM-14169-01-02

Date 2015-10-16

Dipl.-Ing. I. Munkler

TÜV Rheinland LGA Products GmbH - Tillystraße 2 - 90431 Nürnberg
Tel. +49 221 806-1371 Fax +49 221 [illegible] mail: [illegible]@de.tuv.com http://www.tuv.com/safety

KABE LABORTECHNIK

EG-KONFORMITÄTSERKLÄRUNG · EC DECLARATION OF CONFORMITY

Name und Adresse des Herstellers*/Händlers**: Name and address of the manufacturer*/distributor**:	KABE LABORTECHNIK GmbH Jägerhofstraße 17 51588 Nümbrecht-Elsenroth Deutschland / Germany

Wir erklären in alleiniger Verantwortung* bzw. aufgrund der uns vom Hersteller vorliegenden Informationen**,
dass die In-Vitro-Diagnostika der Produktgruppe /
We declare under our sole responsibility* respectively according to the information of the manufacturer**
that the in-vitro-diagnostica of product group

kapillare Blutentnahmesysteme	capillary blood collection systems
• **Kapillarblutentnahmesystem (GK)***	• **capillary blood collection system (GK)***
• **kapillare Probenbehältnisse aus Kunststoff***	• **capillary sample containers made of plastic***
• Blutgaskapillaren (BK)	• blood gas capillaries (BK)
• Hämatokritkapillaren (HK)	• haematocrit capillaries (HK)
• end-to-end Kapillaren (EK)	• end-to-end capillaries (EK)
• **kapillare Probenbehältnisse aus Glas****	• **capillary sample containers made of glass****
• Blutgaskapillaren (BK)	• blood gas capillaries (BK)
• Hämatokritkapillaren (HK)	• haematocrit capillaries (HK)
• end-to-end Kapillaren (EK)	• end-to-end capillaries (EK)
• Mikro-Kapillar-Pipetten mit Ringmarke (RM)	• micro-capillary pipettes with ring mark (RM)

der Klasse / of class	Andere IVD-Produkte Other IVD-devices

den einschlägigen Bestimmungen der IVD-Richtlinie 98/79/EG und deren Umsetzungen in nationale Gesetze entspricht. Die Konformitätserklärung gilt für die durch die KABE LABORTECHNIK GmbH freigegebenen Chargen.

meets the provisions of the directive 98/79/EC and its transpositions in national laws which apply to it. This declaration is valid for the batches released by KABE LABORTECHNIK GmbH.

Konformitätsbewertungsverfahren: Conformity assessment procedure:	Richtlinie 98/79/EG Anhang III Directive 98/79/EC Annex III

SOCIETATEA CU RASPUNDERE LIMITATA * REPUBLICA MOLDOVA * SRL GGG-KLD

KABE LABORTECHNIK GmbH
Jägerhofstraße 17
D-51588 Nümbrecht-Elsenroth
☎ +49 (0) 2293 / 596

Nümbrecht-Elsenroth, 26.07.2018

André Kolpe, Geschäftsführer / Managing director

MEDICA

Medica Corporation
5 Oak Park Drive
Bedford, Massachusetts 01730
Tel 781 275 4892
Fax 781 275 2731
www.medicacorp.com

Products For Health Care

Declaration of Conformity CE

Product Name:	Model/Type:
EasyLyte and accessories per attachment	EasyLyte Na/K, Na/K/Cl, Na/K/Li, Na/K/Cl/Li, Na/K/Ca/pH, Na/K/Cl/Ca/Li
EasyElectrolytes and accessories per attachment	EasyElectrolytes Na/K/Cl, Na/K/Li

Manufacturer

Medica Corporation
5 Oak Park Drive, Bedford, Massachusetts, 01730, USA

Representative

EC REP Emergo Europe, Prinsessegracht 20,
2514 AP The Hague, The Netherlands
Tel: +31 70 345 8570
Fax: +31 70 346 7299

Means of Conformity

Medica Corporation declares that the products listed are covered by Annex III of Directive 98/79/EC. These products are self-certified since they are for professional use only and are not listed on Annex II, List A or Annex II, List B of Directive 98/79/EC. In addition, they are in conformity with the Annex I, "Essential Requirements" and provisions of council Directive 98/79/EC for In Vitro Diagnostic Medical Devices, Directive 2011/65/EU Restriction of Hazardous Substance in Electrical and Electronic Equipment, and the corresponding national laws of the Member States.

Place and Date: Bedford, Massachusetts, USA, March 30, 2017

Signature:

Name: Photios Makris, Ph.D
Title: Director of Regulatory Affairs

EasyLyte Accessories

Catalog No.	Accessory	EDMA Code
2004	EasyLyte Na/K Analyzer	21 07 11 02
2014	EasyLyte Plus Na/K/Cl Analyzer	21 07 11 02
2015	EasyLyte Lithium Na/K/Li Analyzer	21 07 11 02
2016	EasyLyte Calcium Na/K/Ca/pH Analyzer	21 07 11 02
2021	EasyLyte Na/K/Cl/Li Analyzer	21 07 11 02
2030	EasyLyte EXPAND Analyzer, Na/K/Cl/Ca-Li	21 07 11 02
2070	EasyLyte EasySampler	21 07 11 02
2101	EasyLyte K+ Electrode	11 04 01 06
2102	EasyLyte Na+ Electrode	11 04 01 07
2113	EasyLyte Cl- Electrode	11 04 01 03
2106	EasyLyte Li+ Electrode	11 04 01 04
2150	EasyLyte Ca++ Electrode	11 04 01 02
2151	EasyLyte pH Electrode	11 70 31 02
2152	EasyLyte Disposable Reference Electrode	11 04 04 01
2103	EasyLyte Reference Electrode	11 04 04 01
2258	EasyLyte Membrane Assembly	21 07 11 02
2120	EasyLyte Na/K 800 ml Solutions Pack	11 04 04 02
2121	EasyLyte Na/K/Cl 800mL Solutions Pack	11 04 04 02
2122	EasyLyte Na/K/Li 800mL Solutions Pack	11 04 04 02
2123	EasyLyte Na/K/Ca/pH 800mL Solutions Pack	11 04 04 02
2028	EasyLyte Na/K/Cl/Li 400mL Solution Pack	11 04 04 02
2109	EasyLyte Na/K 400mL Solutions Pack	11 04 04 02
2112	EasyLyte Na/K/Cl 400mL Solutions Pack	11 04 04 02
2115	EasyLyte Na/K/Li 400mL Solutions Pack	11 04 04 02
2114	EasyLyte Na/K/Ca/pH 400mL Solutions Pack	11 04 04 02
2026	EasyLyte Na/K/Cl/Li 800mL Solution Pack	11 04 04 02
2124	EasyLyte Na/K/Cl/Ca-Li 800ml Solutions Pack	11 04 04 02
2814	EasyQC Bi-Level Quality Control Kit	11 50 02 04
2815	EasyQC Tri-Level Quality Control Kit	11 50 02 04
2843	EasyLyte Quality Control Sample Cups (60)	21 07 11 02
2118	Daily Cleaning Solution Kit	11 01 01 27
2598	EasyLyte Daily Cleaner Cup	21 07 11 02
2108	EasyLyte Solutions Valve	21 07 11 02
2107	EasyLyte Sample Probe	21 07 11 02
2257	EasyLyte Sample Detector	21 07 11 02

EasyLyte Accessories, continued

Catalog No.	Accessory	EDMA Code
2104	EasyLyte Tubing Kit	21 07 11 02
2100	EasyLyte Calcium Tubing Kit	21 07 11 02
2492	EasyLyte Internal Filling Solution (125mL)	11 04 04 90
2309	EasyLyte Wash Solution (50mL)	11 04 04 90
2111	EasyLyte Urine Diluent (500mL)	11 04 04 90
2577	EasyLyte Standard Solution, Urine (50mL)	11 04 04 90
2323	EasyLyte Probe Wipers (6)	21 07 11 02
2541	EasyLyte Printer Paper (3 rolls)	21 07 11 02
2595	EasyLyte EasySampler Sample Cups, 500uL (500)	21 07 11 02
2596	EasyLyte Sample Cups 2.0mL (500)	21 07 11 02
10745	Anti-Evaporation Caps (500)	21 07 11 02
2293	EasyLyte Capillary Tubes	21 07 11 02
2590	EasyLyte Capillary Adaptor Kit	21 07 11 02
2292	EasyLyte Capillary Adaptor Cleaning Kit	21 07 11 02
2578	EasyLyte Red Dye Test Solution (50mL)	11 30 01 11
2572	EasyLyte Troubleshooting Kit	21 07 11 02
2571	EasyLyte Troubleshooting Kit (Na/K/Ca/pH and Na/K/Cl/Li)	21 07 11 02
2105	EasyLyte Quarterly Operating Kit	21 07 11 02
2095	EasyLyte Maintenace Kit	21 07 11 02
2076	EasyLyte Sample Tray	21 07 11 02
2074	EasyLyte Sample Cup Retainer Ring	21 07 11 02
7118	Daily Rinse/Cleaning Solution Kit	11 01 01 27
2544	EasyLyte C Series Printer Paper (5 rolls)	21 07 11 02
2934	EasyLyte Barcode Reader Kit	21 07 11 02

EasyElectrolyte Accessories

Catalog No.	Accessory	EDMA Code
4002	EasyElectrolytes Na/K/Cl Analyzer	21 07 11 02
4003	EasyElectroiytes Na/K/Li Analyzer	21 07 11 02
4102	EasyElectrolyte Reagent Module Na/K/Cl	11 04 04 02
4103	EasyElectrolyte Reagent Module Na/K/Li	11 04 04 02
7205	EasyStat/EasyElectrolyte Na Electrode	11 04 01 07
7206	EasyStat/EasyElectrolyte K Electrode	11 04 01 06
4203	EasyElectrolyte Cl Electrode	11 04 01 03
4204	EasyElectrolyte Li Electrode	11 04 01 04
6204	EasyStat/EasyBloodGas/EasyElectrolyte Reference Electrode	11 04 04 01
4207	EasyElectrolyte Spacer Electrode	11 04 01 90
4301	EasyElectrolyte Troubleshooting Kit	21 07 11 02
2118	Daily Cleaning Solution Kit	11 01 01 27
4402	Red Test Dye Solution	11 30 01 11
4403	EasyElectrolyte Urine Diluent	11 04 04 90
2814	EasyQC Bi-Level Quality Control Kit	11 50 02 04
2815	EasyQC Tri-Level Quality Control Kit	11 50 02 04
4405	EasyElectrolyte Demonstration Kit, Na/K/Cl	21 07 11 02
4406	EasyElectrolyte Demonstration Kit, Na/K/Li	21 07 11 02
4404	EasyElectrolyte Capillary Tube Kit	21 07 11 02
4306	EasyElectrolyte Sampler	21 07 11 02
6504	EasyBloodGas/EasyElectrolyte Pump Tube	21 07 11 02
6505	EasyStat/EasyBloodGas/EasyElectrolyte Printer Paper (5 rolls)	21 07 11 02
4506	EasyElectrolyte Sensor Module	21 07 11 02
4507	EasyElectrolyte Valve Module	21 07 11 02
4508	Compression Plate	21 07 11 02
7302	Probe Wipers	21 07 11 02
4522	EasyElectrolyte Daily Cleaner Sample Cups	21 07 11 02
4539	EasyElectrolyte Sensor Module, Li	21 07 11 02
6518	Serial Cable, 25-pin	21 07 11 02
6537	Serial Cable, 9-pin	21 07 11 02
6520	Barcode Reader Kit	21 07 11 02

Клиническая биохимия
Агат
105173, Москва, ул. Западная, д. 2, стр. 1, ООО «Агат-Мед».
Тел.: (495) 777-41-92.
Факс: (495) 741-25-19.
www.agat.ru agat@agat.ru

БЕЛОК В МОЧЕ АГАТ

ИНСТРУКЦИЯ
по применению набора реактивов для определения белка в моче с сульфосалициловой кислотой

НАЗНАЧЕНИЕ

Диагностический набор предназначен для количественного определения содержания белка в моче по помутнению, образовавшемуся при добавлении сульфосалициловой кислоты.

Для клинико-диагностических и биохимических лабораторий.

Набор рассчитан на 660 определений при расходе 3,0 мл раствора сульфофосалициловой кислоты на один анализ.

ПРИНЦИП МЕТОДА

Интенсивность помутнения при коагуляции белка сульфосалициловой кислотой, измеренная по оптической плотности при 620 нм, пропорциональна его концентрации.

Калибровка осуществляется по раствору человеческого сывороточного альбумина.

СОСТАВ НАБОРА

1. **5-сульфосалициловая кислота**, дигидрат, 30 г – 2 упаковки;
2. **Калибровочный раствор альбумина 1000 мг/л**, 10 мл – 1 флакон.

ОБОРУДОВАНИЕ И РЕАГЕНТЫ

Спектрофотометр или фотоэлектроколориметр.

АНАЛИЗИРУЕМЫЕ ОБРАЗЦЫ

Моча профильтрованная.

ПОДГОТОВКА РЕАГЕНТОВ ДЛЯ АНАЛИЗА

Раствор сульфосалициловой кислоты. Содержимое одной упаковки (30 г) с сульфосалициловой кислотой количественно переносят в мерную колбу вместимостью 1000 мл, растворяют в дистиллированной воде и доводят объем до метки.

Раствор стабилен.

ПРОВЕДЕНИЕ АНАЛИЗА

В пробирки вносят реактивы по следующей схеме:

Отмерить, мл	Контрольная (холостая) проба	Опытная проба
Образец, профильтрованная моча	1,0	1,0
Раствор сульфосалициловой кислоты	-	3,0
Рствор натрия хлористого, 9 г/л	3,0	-

Содержимое пробирок тщательно перемешивают и выдерживают при температуре +18–22° С в течение 10 минут. Определяют оптическую плотность опытной пробы при длине волны 620 нм (590–650 нм, оранжевый или красный светофильтр) против холостой пробы в кювете с толщиной слоя 10 или 5 мм.

При стоянии образцов более 20 минут возможно уменьшение значений оптической плотности за счет оседания части преципитата. Непосредственно перед измерением пробирку с опытной пробой тщательно встряхнуть. Расчет проводят по калибровочному графику.

Построение калибровочного графика

Для построения калибровочного графика из калибровочного раствора альбумина и 9 г/л раствора натрия хлористого готовят следующие разведения:

№ пробирки	Калибровочный раствор альбумина, мл	9 г/л раствор NaCl, мл	Концентрация белка	
			мг/л	г/л
1	0,25	4,75	50	0,05
2	0,50	4,50	100	0,10
3	1,00	4,00	200	0,20
4	2,50	2,50	500	0,50
5	5,00	-	1000	1,00

Полученные разведения обрабатывают так же, как и образец.

Примечания: Линейная зависимость сохраняется до концентрации белка 1 г/л. При более высоких концентрациях пробу следует развести в 2–3 раза, результат умножить на разведение.

Результаты, получаемые данным методом чувствительны к изменениям температуры. Рекомендуется производить измерения при температуре +18–22° С.

Ложноположительные результаты могут быть получены при наличии в моче контрастных веществ, содержащих органический йод. Поэтому тест нельзя использовать у лиц, принимающих препараты йода. Ложноположительный тест может быть также обусловлен приемом сульфаниламидных препаратов, больших доз пенициллина и при высоких концентрациях в моче мочевой кислоты.

УСЛОВИЯ ХРАНЕНИЯ И ЭКСПЛУАТАЦИИ

Набор следует хранить в упаковке предприятия-изготовителя при температуре +2–8° С в течение всего срока годности.

Срок годности набора – 2 года.

Литература: Лабораторные методы исследования в клинике. Под редакцией проф. В.В. Меньшикова, М., 1987, с. 49.

По вопросам, касающимся приобретения наборов и их качества, просим обращаться по адресу: 105173, г. Москва, ул. Западная, д. 2, стр. 1, ООО «Агат–Мед». Телефон для справок: (495) 777-41-92.

Инструкция составлена: к.б.н. И.В. Смирновым – зав. лабораторией ГНЦ РАМН, В.В. Гладуном – главным технологом ООО «Агат-Мед».

GOST R CERTIFICATION SYSTEM
FEDERAL AGENCY FOR TECHNIQUE REGULATION AND METROLOGY

VOLUNTARY CERTIFICATION SYSTEM
"SMK-STANDARD"
Reg. No. РОСС RU.31060.04ЖЖЮ0

Certification authority:
REG No. SMK STANDART.RU.0005
INTERNATIONAL CERTIFICATION CENTER Limited Liability Company
Address: 138, Naberezhnaya Obvodnogo Canala, block 1, office 421, St. Petersburg, 190020
phone: +7 (812) 438-76-71 standart@iso-smk.ru
Check the authenticity of the certificate in the register on the website http://www.iso-smk.ru

CERTIFICATE OF CONFORMITY

No. ST.RU.0001.M0013380

This Certificate of Conformity is issued to

Agat-Med, Ltd.
Address: 6, Glavnaya st., Moscow, 105173, Russia
TRN 7719187311 OGRN 1037739078970

Date of issue: 26.01.2018 Period of validity: 26.01.2021

This certificate certifies that:

Medical devices. Quality management system. System requirements for regulatory purposes in relation to the works in accordance with Annex 1 to this certificate

(the attachment is an integral part of the certificate)

CORRESPONDS TO THE REQUIREMENTS OF GOST ISO 13485-2011 (EN ISO 13485:2003)

Manager of "Expert" authority **V.V. Koptsev** **O.V. Gundareva**

THIS CERTIFICATE BINDS THE ORGANIZATION TO MAINTAIN THE WORKS PERFORMED ACCORDING TO THE STANDARD MENTIONED ABOVE, TO BE CONTROLLED BY THE INSTITUTIONAL BODY OF VOLUNTARY CERTIFICATION SYSTEM "SMK STANDARD" AND IS CONFIRMED DURING THE ANNUAL INSPECTION CONTROL

A qui de droit / *To whom it may concern*

DECLARATION DE CONFORMITE CE
DECLARATION OF EUROPEAN CONFORMITY

REACTIFS & INSTRUMENTS DE LABORATOIRE
LABORATORY REAGENTS & INSTRUMENTS

Je soussigné, Isabelle Oget, Directrice des Affaires Réglementaires de BIOLABO S.A.S., certifie par la présente que nos Réactifs Code HS 3822 00 00 et Instruments sont fabriqués par la société BIOLABO S.A.S sur le site de Maizy (F-02160) pour une distribution mondiale incluant l'Union Européenne.

I, the undersigned, Mrs Oget Isabelle, Regulatory Affairs Director of BIOLABO S.A.S, certify that our Reagents HS Code 3822 00 00 and Instruments are manufactured by BIOLABO S.A.S in its Maizy facilities (Les Hautes Rives, F-02160, France) for a world-wide distribution including European Union (EU).

1) La procédure de déclaration de conformité suivie est conforme aux indications de l'Annexe III de la Directive Européenne DMDIV 98/79/CE.

   The conformity assessment procedure being followed is Annex III of the IVD Directive 98/79/EC

2) Les Produits désignés **(CONFORMEMENT A L' ANNEXE, 5 PAGES)** sont classés comme suit :

   Autres dispositifs (tous dispositif, sauf Annexe II et autotests)

   *These products (**ACCORDING TO ATTACHED LIST, 5 PAGES**) are classified as follows:*
   Other devices (all devices, except Annex II and self testing devices)

3) Ces produits remplissent toutes les exigences essentielles (Annexe I) de la Directive Européenne DMDIV 98/79/CE.

   These products fulfil the essential requirements (Annexe I) of European Directive IVDMD 98/79/EC.

4) Ces exigences sont documentées à l'aide de dossiers techniques incluant les informations suivantes :

   Essential requirements are reviewed by checking the technical files, including the following information:

   - Dossier de revue de conformité aux Exigences Essentielles.
     File for checking Essential Requirements of above mentioned European Directive.
   - Dossier de conception
     File for device's design
   - Dossier Performances (spécifications techniques)
     File for performance (technical specifications).
   - Description des Processus dans le Système Qualité
   - *Process management (BIOLABO Standard Operating Procedures, ISO 9001:2008 & 13485:2003 certified)*
   - Référentiel d'étiquetage, Référentiel des notices
   - *Labelling instructions and references, Package inserts instructions and references.*
   - Dossiers de suivi des lots et retour d'information des utilisateurs.
     File for batches Traceability including customer's information
   - Dossier d'analyse des risques, basé sur le référentiel EN ISO 14971.
     Risk Analysis, based on EN ISO 14971.

5) Le référentiel qualité de BIOLABO S.A.S. est certifié ISO 9001:2008 sous le No 1999/12367.10 et ISO 13485 :2003 sous le numéro n° 2008/31601.4 par l'AFAQ (Association Française pour l'Assurance Qualité).

   BIOLABO S.A.S Quality System Management is ISO 9001:2008 certified under No 1999/12367.10 and ISO 13485:2003 certified under n° 2008/31601.4, by AFAQ (French Association for Quality Assurance).

6) Je déclare exactes et sincères les informations de la présente déclaration, certifiant que les produits désignés ci-dessus sont conformes aux exigences de la directive européenne 98/79/CE, lesquelles exigences sont intégralement remplies et documentées

   I declare that the above information is true and sincere, certifying the product mentioned above fully comply with European Directive 98/79/CE

7) Je m'engage à mettre à la disposition des autorités compétentes de la République Française tout élément d'information qui me serait demandé, y compris dans le cadre de vérifications requises par leurs homologues étrangers.

   I commit myself to provide to competent French Republic authorities any information which would be requested related to this product, whatever is the origin of such request which may come from their foreign homologues.

La présente déclaration est établie à Maizy, France, le 11 septembre 2017 et pour valoir ce que de droit

This Declaration is issued at Maizy, France, on 11 September 2017.

BIOLABO S.A.S.
Les Hautes Rives
02160 MAIZY - FRANCE
Phone : (33) 03 23 25 15 50
Fax : (33) 03 23 25 62 56
Siret 317 398 832 00038
TVA : FR 82 317 398 832

I. OGET

DIRECTION DES AFFAIRES REGLEMENTAIRES
REGULATORY AFFAIRS DIRECTOR

Adress : Les Hautes Rives F-02160 MAIZY (FRANCE) - Phone. : (33) 03 23 25 15 50 - Fax : (33) 03 23 25 62 56
BIOLABO S.A.S with a capital of 119700 € - SIRET 317 398 832 00038 - VAT : FR 82 317 398 832 - NAF 2059Z
WEB : http://www.biolabo.fr email : info@biolabo.fr